{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:46:48Z","timestamp":1785916008240,"version":"3.56.0"},"reference-count":305,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"DOI":"10.7759\/cureus.113978","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:04:02Z","timestamp":1785913442000},"source":"Crossref","is-referenced-by-count":0,"title":["Minimal Hepatic Encephalopathy: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Jamir","family":"Pitton Rissardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Moharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Leticia","family":"Fornari Caprara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A","family":"Chouthai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Kedwany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagar H","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omesh","family":"Prathiraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maleesha","family":"Jayasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani SK","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019, 70:151-71. 10.1016\/j.jhep.2018.09.014","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi H","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023, 79:516-37. 10.1016\/j.jhep.2023.03.017","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.042","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases","volume":"61","year":"2014","unstructured":"Hepatic encephalopathy in chronic liver disease. 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014, 61:642-59. 10.1016\/j.jhep.2014.05.042","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nly061","article-title":"Histological features of cerebellar neuropathology in patients with alcoholic and nonalcoholic steatohepatitis","volume":"77","author":"Balzano T","year":"2018","unstructured":"Balzano T, Forteza J, Borreda I, et al.. Histological features of cerebellar neuropathology in patients with alcoholic and nonalcoholic steatohepatitis. J Neuropathol Exp Neurol. 2018, 77:837-45. 10.1093\/jnen\/nly061","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.09.005","article-title":"Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure","volume":"62","author":"Romero-G\u00f3mez M","year":"2015","unstructured":"Romero-G\u00f3mez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015, 62:437-47. 10.1016\/j.jhep.2014.09.005","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00026-5","article-title":"Neuropsychological characterization of hepatic encephalopathy","volume":"34","author":"Weissenborn K","year":"2001","unstructured":"Weissenborn K, Ennen JC, Schomerus H, R\u00fcckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001, 34:768-73. 10.1016\/S0168-8278(01)00026-5","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04590.x","article-title":"Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement","volume":"33","author":"Bajaj JS","year":"2011","unstructured":"Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011, 33:739-47. 10.1111\/j.1365-2036.2011.04590.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1023\/b:mebr.0000043975.01841.de","article-title":"Characteristics of minimal hepatic encephalopathy","volume":"19","author":"Amodio P","year":"2004","unstructured":"Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis. 2004, 19:253-67. 10.1023\/b:mebr.0000043975.01841.de","journal-title":"Metab Brain Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2018.0232","article-title":"The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies","volume":"31","author":"Ridola L","year":"2018","unstructured":"Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies. Ann Gastroenterol. 2018, 31:151-64. 10.20524\/aog.2018.0232","journal-title":"Ann Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-015-9688-7","article-title":"Minimal hepatic encephalopathy characterized by parallel use of the continuous reaction time and portosystemic encephalopathy tests","volume":"30","author":"Lauridsen MM","year":"2015","unstructured":"Lauridsen MM, Schaffalitzky de Muckadell OB, Vilstrup H. Minimal hepatic encephalopathy characterized by parallel use of the continuous reaction time and portosystemic encephalopathy tests. Metab Brain Dis. 2015, 30:1187-92. 10.1007\/s11011-015-9688-7","journal-title":"Metab Brain Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1888-3","article-title":"Driving simulation can improve insight into impaired driving skills in cirrhosis","volume":"57","author":"Bajaj JS","year":"2012","unstructured":"Bajaj JS, Thacker LR, Heuman DM, et al.. Driving simulation can improve insight into impaired driving skills in cirrhosis. Dig Dis Sci. 2012, 57:554-60. 10.1007\/s10620-011-1888-3","journal-title":"Dig Dis Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2018.6","article-title":"Diagnosis of minimal hepatic encephalopathy: a systematic review of point-of-care diagnostic tests","volume":"113","author":"Tapper EB","year":"2018","unstructured":"Tapper EB, Parikh ND, Waljee AK, Volk M, Carlozzi NE, Lok AS. Diagnosis of minimal hepatic encephalopathy: a systematic review of point-of-care diagnostic tests. Am J Gastroenterol. 2018, 113:529-38. 10.1038\/ajg.2018.6","journal-title":"Am J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.03.023","article-title":"Normal protein diet for episodic hepatic encephalopathy: results of a randomized study","volume":"41","author":"C\u00f3rdoba J","year":"2004","unstructured":"C\u00f3rdoba J, L\u00f3pez-Hell\u00edn J, Planas M, et al.. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004, 41:38-43. 10.1016\/j.jhep.2004.03.023","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.08.028","article-title":"Muscle wasting is associated with mortality in patients with cirrhosis","volume":"10","author":"Montano-Loza AJ","year":"2012","unstructured":"Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, Sawyer MB. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012, 10:166-73, 173.e1. 10.1016\/j.cgh.2011.08.028","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.7.1041","article-title":"Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver","volume":"52","author":"Jalan R","year":"2003","unstructured":"Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut. 2003, 52:1041-5. 10.1136\/gut.52.7.1041","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5049\/EBP.2011.9.2.45","article-title":"Mechanisms of the effects of acidosis and hypokalemia on renal ammonia metabolism","volume":"9","author":"Han KH","year":"2011","unstructured":"Han KH. Mechanisms of the effects of acidosis and hypokalemia on renal ammonia metabolism. Electrolyte Blood Press. 2011, 9:45-9. 10.5049\/EBP.2011.9.2.45","journal-title":"Electrolyte Blood Press"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-016-9938-3","article-title":"Ammonia toxicity: from head to toe?","volume":"32","author":"Dasarathy S","year":"2017","unstructured":"Dasarathy S, Mookerjee RP, Rackayova V, Rangroo Thrane V, Vairappan B, Ott P, Rose CF. Ammonia toxicity: from head to toe?. Metab Brain Dis. 2017, 32:529-38. 10.1007\/s11011-016-9938-3","journal-title":"Metab Brain Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10311013","article-title":"Urea and ammonia metabolism and the control of renal nitrogen excretion","volume":"10","author":"Weiner ID","year":"2015","unstructured":"Weiner ID, Mitch WE, Sands JM. Urea and ammonia metabolism and the control of renal nitrogen excretion. Clin J Am Soc Nephrol. 2015, 10:1444-58. 10.2215\/CJN.10311013","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016645826","article-title":"Management of hepatic encephalopathy: a primer","volume":"50","author":"Jawaro T","year":"2016","unstructured":"Jawaro T, Yang A, Dixit D, Bridgeman MB. Management of hepatic encephalopathy: a primer. Ann Pharmacother. 2016, 50:569-77. 10.1177\/1060028016645826","journal-title":"Ann Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250609","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study","volume":"25","author":"Kircheis G","year":"1997","unstructured":"Kircheis G, Nilius R, Held C, et al.. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997, 25:1351-60. 10.1002\/hep.510250609","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2006.02.008","article-title":"The challenge of understanding ammonium homeostasis and the role of the Rh glycoproteins","volume":"13","author":"Bakouh N","year":"2006","unstructured":"Bakouh N, Benjelloun F, Cherif-Zahar B, Planelles G. The challenge of understanding ammonium homeostasis and the role of the Rh glycoproteins. Transfus Clin Biol. 2006, 13:139-46. 10.1016\/j.tracli.2006.02.008","journal-title":"Transfus Clin Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609343200","article-title":"Fast and selective ammonia transport by aquaporin-8","volume":"282","author":"Saparov SM","year":"2007","unstructured":"Saparov SM, Liu K, Agre P, Pohl P. Fast and selective ammonia transport by aquaporin-8. J Biol Chem. 2007, 282:5296-301. 10.1074\/jbc.M609343200","journal-title":"J Biol Chem"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00019-9","article-title":"Neurobiology of ammonia","volume":"67","author":"Felipo V","year":"2002","unstructured":"Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol. 2002, 67:259-79. 10.1016\/S0301-0082(02)00019-9","journal-title":"Prog Neurobiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21357","article-title":"Glutamine: a Trojan horse in ammonia neurotoxicity","volume":"44","author":"Albrecht J","year":"2006","unstructured":"Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology. 2006, 44:788-94. 10.1002\/hep.21357","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02293.x","article-title":"Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration","volume":"30","author":"Guevara M","year":"2010","unstructured":"Guevara M, Baccaro ME, R\u00edos J, et al.. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. 2010, 30:1137-42. 10.1111\/j.1478-3231.2010.02293.x","journal-title":"Liver Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.107","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"109","author":"Umapathy S","year":"2014","unstructured":"Umapathy S, Dhiman RK, Grover S, Duseja A, Chawla YK. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Am J Gastroenterol. 2014, 109:1011-9. 10.1038\/ajg.2014.107","journal-title":"Am J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1017-0","article-title":"Hepatic encephalopathy in cirrhosis: pathology and pathophysiology","volume":"79","author":"Butterworth RF","year":"2019","unstructured":"Butterworth RF. Hepatic encephalopathy in cirrhosis: pathology and pathophysiology. Drugs. 2019, 79:17-21. 10.1007\/s40265-018-1017-0","journal-title":"Drugs"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-007-9072-3","article-title":"Neuronal cell death in hepatic encephalopathy","volume":"22","author":"Butterworth R","year":"2007","unstructured":"Butterworth R. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis. 2007, 22:309-20. 10.1007\/s11011-007-9072-3","journal-title":"Metab Brain Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01477-8","article-title":"Correlation between ammonia levels and the severity of hepatic encephalopathy","volume":"114","author":"Ong JP","year":"2003","unstructured":"Ong JP, Aggarwal A, Krieger D, et al.. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003, 114:188-93. 10.1016\/S0002-9343(02)01477-8","journal-title":"Am J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1159\/000112104","article-title":"Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures","volume":"16","author":"Chao CC","year":"1994","unstructured":"Chao CC, Hu S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev Neurosci. 1994, 16:172-9. 10.1159\/000112104","journal-title":"Dev Neurosci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.012","article-title":"Increased risk of cognitive impairment in cirrhotic patients with bacterial infections","volume":"59","author":"Merli M","year":"2013","unstructured":"Merli M, Lucidi C, Pentassuglio I, et al.. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. J Hepatol. 2013, 59:243-50. 10.1016\/j.jhep.2013.03.012","journal-title":"J Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20194","article-title":"Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis","volume":"39","author":"Liu Q","year":"2004","unstructured":"Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004, 39:1441-9. 10.1002\/hep.20194","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.033","article-title":"Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis","volume":"156","author":"Bajaj JS","year":"2019","unstructured":"Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology. 2019, 156:1921-1923.e3. 10.1053\/j.gastro.2019.01.033","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(02)00027-X","article-title":"Glutamate transporters in hyperammonemia","volume":"41","author":"Butterworth RF","year":"2002","unstructured":"Butterworth RF. Glutamate transporters in hyperammonemia. Neurochem Int. 2002, 41:81-5. 10.1016\/S0197-0186(02)00027-X","journal-title":"Neurochem Int"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(90)90403-Q","article-title":"Neurochemical and electrophysiological studies on the inhibitory effect of ammonium ions on synaptic transmission in slices of rat hippocampus: evidence for a postsynaptic action","volume":"37","author":"Fan P","year":"1990","unstructured":"Fan P, Lavoie J, L\u00e9 NL, Szerb JC, Butterworth RF. Neurochemical and electrophysiological studies on the inhibitory effect of ammonium ions on synaptic transmission in slices of rat hippocampus: evidence for a postsynaptic action. Neuroscience. 1990, 37:327-34. 10.1016\/0306-4522(90)90403-Q","journal-title":"Neuroscience"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2013.02.010","article-title":"Neurotransmitter receptor alterations in hepatic encephalopathy: a review","volume":"536","author":"Palomero-Gallagher N","year":"2013","unstructured":"Palomero-Gallagher N, Zilles K. Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch Biochem Biophys. 2013, 536:109-21. 10.1016\/j.abb.2013.02.010","journal-title":"Arch Biochem Biophys"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/BF01391377","article-title":"Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy","volume":"27","author":"Cascino A","year":"1982","unstructured":"Cascino A, Cangiano C, Fiaccadori F, et al.. Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy. Dig Dis Sci. 1982, 27:828-32. 10.1007\/BF01391377","journal-title":"Dig Dis Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1987.tb10018.x","article-title":"Ammonia-induced release of neurotransmitters from rat brain synaptosomes: differences between the effects on amines and amino acids","volume":"49","author":"Ereci\u0144ska M","year":"1987","unstructured":"Ereci\u0144ska M, Pastuszko A, Wilson DF, Nelson D. Ammonia-induced release of neurotransmitters from rat brain synaptosomes: differences between the effects on amines and amino acids. J Neurochem. 1987, 49:1258-65. 10.1111\/j.1471-4159.1987.tb10018.x","journal-title":"J Neurochem"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2010.09.012","article-title":"Inflammation-associated depression: from serotonin to kynurenine","volume":"36","author":"Dantzer R","year":"2011","unstructured":"Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011, 36:426-36. 10.1016\/j.psyneuen.2010.09.012","journal-title":"Psychoneuroendocrinology"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1023\/a:1021909902310","article-title":"Nitric oxide in liver inflammation and regeneration","volume":"17","author":"Martin-Sanz P","year":"2002","unstructured":"Martin-Sanz P, Hortelano S, Callejas NA, Goren N, Casado M, Zeini M, Bosc\u00e1 L. Nitric oxide in liver inflammation and regeneration. Metab Brain Dis. 2002, 17:325-34. 10.1023\/a:1021909902310","journal-title":"Metab Brain Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2013.04.013","article-title":"Hepatic encephalopathy: clinical aspects and pathogenetic concept","volume":"536","author":"H\u00e4ussinger D","year":"2013","unstructured":"H\u00e4ussinger D, Sies H. Hepatic encephalopathy: clinical aspects and pathogenetic concept. Arch Biochem Biophys. 2013, 536:97-100. 10.1016\/j.abb.2013.04.013","journal-title":"Arch Biochem Biophys"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00073.2015","article-title":"GR3027 antagonizes GABAA receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy","volume":"309","author":"Johansson M","year":"2015","unstructured":"Johansson M, Agusti A, Llansola M, et al.. GR3027 antagonizes GABAA receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2015, 309:G400-9. 10.1152\/ajpgi.00073.2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1023\/a:1021974321874","article-title":"Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy","volume":"17","author":"Spahr L","year":"2002","unstructured":"Spahr L, Burkhard PR, Gr\u00f6tzsch H, Hadengue A. Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy. Metab Brain Dis. 2002, 17:399-413. 10.1023\/a:1021974321874","journal-title":"Metab Brain Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13442","article-title":"Manganese neurotoxicity: behavioral disorders associated with dysfunctions in the basal ganglia and neurochemical transmission","volume":"136","author":"Bouabid S","year":"2016","unstructured":"Bouabid S, Tinakoua A, Lakhdar-Ghazal N, Benazzouz A. Manganese neurotoxicity: behavioral disorders associated with dysfunctions in the basal ganglia and neurochemical transmission. J Neurochem. 2016, 136:677-91. 10.1111\/jnc.13442","journal-title":"J Neurochem"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/poh2.65","article-title":"Prevalence and risk factors for minimal hepatic encephalopathy in cirrhotic patients with different etiologies","volume":"2","author":"Li X","year":"2023","unstructured":"Li X, Liu S, Xiang H, et al.. Prevalence and risk factors for minimal hepatic encephalopathy in cirrhotic patients with different etiologies. Portal hypertens cirrhosis. 2023, 2:171-80. 10.1002\/poh2.65","journal-title":"Portal hypertens cirrhosis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-016-0487-3","article-title":"Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study","volume":"16","author":"Jepsen P","year":"2016","unstructured":"Jepsen P, Christensen J, Weissenborn K, Watson H, Vilstrup H. Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study. BMC Gastroenterol. 2016, 16:77. 10.1186\/s12876-016-0487-3","journal-title":"BMC Gastroenterol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.09.011","article-title":"Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis","volume":"118","author":"Chang KV","year":"2019","unstructured":"Chang KV, Chen JD, Wu WT, Huang KC, Lin HY, Han DS. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis. J Formos Med Assoc. 2019, 118:833-42. 10.1016\/j.jfma.2018.09.011","journal-title":"J Formos Med Assoc"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-006-9042-1","article-title":"Role of ammonia and inflammation in minimal hepatic encephalopathy","volume":"22","author":"Shawcross DL","year":"2007","unstructured":"Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007, 22:125-38. 10.1007\/s11011-006-9042-1","journal-title":"Metab Brain Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31815e7f58","article-title":"IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy","volume":"43","author":"Montoliu C","year":"2009","unstructured":"Montoliu C, Piedrafita B, Serra MA, del Olmo JA, Urios A, Rodrigo JM, Felipo V. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol. 2009, 43:272-9. 10.1097\/MCG.0b013e31815e7f58","journal-title":"J Clin Gastroenterol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-011-9269-3","article-title":"Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy","volume":"27","author":"Felipo V","year":"2012","unstructured":"Felipo V, Urios A, Montesinos E, et al.. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis. 2012, 27:51-8. 10.1007\/s11011-011-9269-3","journal-title":"Metab Brain Dis"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.579263","article-title":"Cognitive impairment after resolution of hepatic encephalopathy: a systematic review and meta-analysis","volume":"15","author":"L\u00f3pez-Franco \u00d3","year":"2021","unstructured":"L\u00f3pez-Franco \u00d3, Morin JP, Cort\u00e9s-Sol A, et al.. Cognitive impairment after resolution of hepatic encephalopathy: a systematic review and meta-analysis. Front Neurosci. 2021, 15:579263. 10.3389\/fnins.2021.579263","journal-title":"Front Neurosci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3587","article-title":"Hepatic encephalopathy: effects of liver failure on brain function","volume":"14","author":"Felipo V","year":"2013","unstructured":"Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nat Rev Neurosci. 2013, 14:851-8. 10.1038\/nrn3587","journal-title":"Nat Rev Neurosci"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.24788","article-title":"Altered intrinsic brain activity in patients with hepatic encephalopathy","volume":"99","author":"Cao Y","year":"2021","unstructured":"Cao Y, Wu B, Chen T, Diao W, Jia Z. Altered intrinsic brain activity in patients with hepatic encephalopathy. J Neurosci Res. 2021, 99:1337-53. 10.1002\/jnr.24788","journal-title":"J Neurosci Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12120026","article-title":"Brain dysfunction primarily related to previous overt hepatic encephalopathy compared with minimal hepatic encephalopathy: resting-state functional MR imaging demonstration","volume":"266","author":"Chen HJ","year":"2013","unstructured":"Chen HJ, Jiao Y, Zhu XQ, Zhang HY, Liu JC, Wen S, Teng GJ. Brain dysfunction primarily related to previous overt hepatic encephalopathy compared with minimal hepatic encephalopathy: resting-state functional MR imaging demonstration. Radiology. 2013, 266:261-70. 10.1148\/radiol.12120026","journal-title":"Radiology"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen RC","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999, 56:303-8. 10.1001\/archneur.56.3.303","journal-title":"Arch Neurol"},{"key":"ref56","doi-asserted-by":"crossref","DOI":"10.1016\/0016-5085(78)90851-X","article-title":"Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism","volume":"75","author":"Rikkers L","year":"1978","unstructured":"Rikkers L, Jenko P, Rudman D, Freides D. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology. 1978, 75:462-9.","journal-title":"Gastroenterology"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/BF01367675","article-title":"Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive","volume":"26","author":"Schomerus H","year":"1981","unstructured":"Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, D\u00f6lle W. Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci. 1981, 26:622-30. 10.1007\/BF01367675","journal-title":"Dig Dis Sci"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00295-2","article-title":"Memory function in early hepatic encephalopathy","volume":"39","author":"Weissenborn K","year":"2003","unstructured":"Weissenborn K, Heidenreich S, Giewekemeyer K, R\u00fcckert N, Hecker H. Memory function in early hepatic encephalopathy. J Hepatol. 2003, 39:320-5. 10.1016\/S0168-8278(03)00295-2","journal-title":"J Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80257-3","article-title":"\u201cWhat\u2019s in a name?\u201d Improving the care of cirrhotics","volume":"32","author":"Lockwood AH","year":"2000","unstructured":"Lockwood AH. \u201cWhat\u2019s in a name?\u201d Improving the care of cirrhotics. J Hepatol. 2000, 32:859-61. 10.1016\/S0168-8278(00)80257-3","journal-title":"J Hepatol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci P","year":"2002","unstructured":"Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002, 35:716-21. 10.1053\/jhep.2002.31250","journal-title":"Hepatology"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass NM","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, et al.. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010, 362:1071-81. 10.1056\/NEJMoa0907893","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3609","article-title":"Minimal hepatic encephalopathy matters in daily life","volume":"14","author":"Bajaj JS","year":"2008","unstructured":"Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol. 2008, 14:3609-15. 10.3748\/wjg.14.3609","journal-title":"World J Gastroenterol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23128","article-title":"Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test","volume":"50","author":"Bajaj JS","year":"2009","unstructured":"Bajaj JS, Saeian K, Schubert CM, et al.. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009, 50:1175-83. 10.1002\/hep.23128","journal-title":"Hepatology"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i27.3347","article-title":"Changing face of hepatic encephalopathy: role of inflammation and oxidative stress","volume":"16","author":"Seyan AS","year":"2010","unstructured":"Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol. 2010, 16:3347-57. 10.3748\/wjg.v16.i27.3347","journal-title":"World J Gastroenterol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03375.x","article-title":"Development and evaluation of the liver disease quality of life instrument in persons with advanced chronic liver disease\u2014the LDQOL 1.0","volume":"95","author":"Gralnek IM","year":"2000","unstructured":"Gralnek IM, Hays RD, Kilbourne A, et al.. Development and evaluation of the liver disease quality of life instrument in persons with advanced chronic liver disease\u2014the LDQOL 1.0. Am J Gastroenterol. 2000, 95:3552-65. 10.1111\/j.1572-0241.2000.03375.x","journal-title":"Am J Gastroenterol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi ZM","year":"1999","unstructured":"Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999, 45:295-300. 10.1136\/gut.45.2.295","journal-title":"Gut"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280108","article-title":"Subclinical hepatic encephalopathy impairs daily functioning","volume":"28","author":"Groeneweg M","year":"1998","unstructured":"Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, Schalm SW. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998, 28:45-9. 10.1002\/hep.510280108","journal-title":"Hepatology"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.19067","article-title":"Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease","volume":"32","author":"Kim WR","year":"2000","unstructured":"Kim WR, Lindor KD, Malinchoc M, Petz JL, Jorgensen R, Dickson ER. Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. Hepatology. 2000, 32:924-9. 10.1053\/jhep.2000.19067","journal-title":"Hepatology"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12227","article-title":"Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis","volume":"44","author":"Mina A","year":"2014","unstructured":"Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. Hepatol Res. 2014, 44:E92-9. 10.1111\/hepr.12227","journal-title":"Hepatol Res"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.061","article-title":"Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy","volume":"140","author":"Bajaj JS","year":"2011","unstructured":"Bajaj JS, Heuman DM, Wade JB, et al.. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011, 140:478-487.e1. 10.1053\/j.gastro.2010.08.061","journal-title":"Gastroenterology"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26555","article-title":"Sleep-wake abnormalities in patients with cirrhosis","volume":"59","author":"Montagnese S","year":"2014","unstructured":"Montagnese S, De Pitt\u00e0 C, De Rui M, et al.. Sleep-wake abnormalities in patients with cirrhosis. Hepatology. 2014, 59:705-12. 10.1002\/hep.26555","journal-title":"Hepatology"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02089.x","article-title":"Night-time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis","volume":"29","author":"Montagnese S","year":"2009","unstructured":"Montagnese S, Middleton B, Skene DJ, Morgan MY. Night-time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. Liver Int. 2009, 29:1372-82. 10.1111\/j.1478-3231.2009.02089.x","journal-title":"Liver Int"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.06.013","article-title":"Neuropsychological abnormalities in cirrhosis include learning impairment","volume":"44","author":"Ortiz M","year":"2006","unstructured":"Ortiz M, C\u00f3rdoba J, Jacas C, Flavi\u00e0 M, Esteban R, Guardia J. Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol. 2006, 44:104-10. 10.1016\/j.jhep.2005.06.013","journal-title":"J Hepatol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1023\/a:1014000313824","article-title":"Correlations between cerebral glucose metabolism and neuropsychological test performance in nonalcoholic cirrhotics","volume":"17","author":"Lockwood AH","year":"2002","unstructured":"Lockwood AH, Weissenborn K, Bokemeyer M, Tietge U, Burchert W. Correlations between cerebral glucose metabolism and neuropsychological test performance in nonalcoholic cirrhotics. Metab Brain Dis. 2002, 17:29-40. 10.1023\/a:1014000313824","journal-title":"Metab Brain Dis"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20565","article-title":"Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts","volume":"41","author":"Erceg S","year":"2005","unstructured":"Erceg S, Monfort P, Hern\u00e1ndez-Viadel M, Rodrigo R, Montoliu C, Felipo V. Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts. Hepatology. 2005, 41:299-306. 10.1002\/hep.20565","journal-title":"Hepatology"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80612-9","article-title":"Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance","volume":"21","author":"Srivastava A","year":"1994","unstructured":"Srivastava A, Mehta R, Rothke SP, Rademaker AW, Blei AT. Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance. J Hepatol. 1994, 21:1023-8. 10.1016\/S0168-8278(05)80612-9","journal-title":"J Hepatol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22032","article-title":"Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy","volume":"47","author":"Bajaj JS","year":"2008","unstructured":"Bajaj JS, Hafeezullah M, Hoffmann RG, et al.. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology. 2008, 47:596-604. 10.1002\/hep.22032","journal-title":"Hepatology"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.413","article-title":"Minimal hepatic encephalopathy is associated with falls","volume":"106","author":"Rom\u00e1n E","year":"2011","unstructured":"Rom\u00e1n E, C\u00f3rdoba J, Torrens M, et al.. Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol. 2011, 106:476-82. 10.1038\/ajg.2010.413","journal-title":"Am J Gastroenterol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25554","article-title":"Cognitive dysfunction in cirrhosis is associated with falls: a prospective study","volume":"55","author":"Soriano G","year":"2012","unstructured":"Soriano G, Rom\u00e1n E, C\u00f3rdoba J, et al.. Cognitive dysfunction in cirrhosis is associated with falls: a prospective study. Hepatology. 2012, 55:1922-30. 10.1002\/hep.25554","journal-title":"Hepatology"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21852","article-title":"Bone disorders in chronic liver disease","volume":"46","author":"Collier J","year":"2007","unstructured":"Collier J. Bone disorders in chronic liver disease. Hepatology. 2007, 46:1271-8. 10.1002\/hep.21852","journal-title":"Hepatology"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80243-3","article-title":"Screening of subclinical hepatic encephalopathy","volume":"32","author":"Groeneweg M","year":"2000","unstructured":"Groeneweg M, Moerland W, Quero JC, Hop WC, Krabbe PF, Schalm SW. Screening of subclinical hepatic encephalopathy. J Hepatol. 2000, 32:748-53. 10.1016\/S0168-8278(00)80243-3","journal-title":"J Hepatol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy","volume":"25","author":"Poordad FF","year":"2007","unstructured":"Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007, 25:3-9. 10.1111\/j.1746-6342.2006.03215.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21586","article-title":"Value of the critical flicker frequency in patients with minimal hepatic encephalopathy","volume":"45","author":"Romero-G\u00f3mez M","year":"2007","unstructured":"Romero-G\u00f3mez M, C\u00f3rdoba J, Jover R, et al.. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007, 45:879-85. 10.1002\/hep.21586","journal-title":"Hepatology"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-009-0003-6","article-title":"Minimal hepatic encephalopathy","volume":"28","author":"Dhiman RK","year":"2009","unstructured":"Dhiman RK, Chawla YK. Minimal hepatic encephalopathy. Indian J Gastroenterol. 2009, 28:5-16. 10.1007\/s12664-009-0003-6","journal-title":"Indian J Gastroenterol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2016.04.009","article-title":"Minimal hepatic encephalopathy: a review","volume":"111","author":"Nardone R","year":"2016","unstructured":"Nardone R, Taylor AC, H\u00f6ller Y, Brigo F, Lochner P, Trinka E. Minimal hepatic encephalopathy: a review. Neurosci Res. 2016, 111:1-12. 10.1016\/j.neures.2016.04.009","journal-title":"Neurosci Res"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20095","article-title":"Minimal hepatic encephalopathy impairs fitness to drive","volume":"39","author":"Wein C","year":"2004","unstructured":"Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology. 2004, 39:739-45. 10.1002\/hep.20095","journal-title":"Hepatology"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23216","article-title":"Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy","volume":"50","author":"Bajaj JS","year":"2009","unstructured":"Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009, 50:2014-21. 10.1002\/hep.23216","journal-title":"Hepatology"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i35.5257","article-title":"Sarcopenia and cognitive impairment in liver cirrhosis: a viewpoint on the clinical impact of minimal hepatic encephalopathy","volume":"25","author":"Nardelli S","year":"2019","unstructured":"Nardelli S, Gioia S, Faccioli J, Riggio O, Ridola L. Sarcopenia and cognitive impairment in liver cirrhosis: a viewpoint on the clinical impact of minimal hepatic encephalopathy. World J Gastroenterol. 2019, 25:5257-65. 10.3748\/wjg.v25.i35.5257","journal-title":"World J Gastroenterol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1249-7","article-title":"Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver","volume":"55","author":"Dhiman RK","year":"2010","unstructured":"Dhiman RK, Kurmi R, Thumburu KK, Venkataramarao SH, Agarwal R, Duseja A, Chawla Y. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. 2010, 55:2381-90. 10.1007\/s10620-010-1249-7","journal-title":"Dig Dis Sci"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1093\/arclin\/acv052","article-title":"Regression-based normative formulae for the repeatable battery for the assessment of neuropsychological status for older adults","volume":"30","author":"Duff K","year":"2015","unstructured":"Duff K, Ramezani A. Regression-based normative formulae for the repeatable battery for the assessment of neuropsychological status for older adults. Arch Clin Neuropsychol. 2015, 30:600-4. 10.1093\/arclin\/acv052","journal-title":"Arch Clin Neuropsychol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29146","article-title":"The animal naming test: an easy tool for the assessment of hepatic encephalopathy","volume":"66","author":"Campagna F","year":"2017","unstructured":"Campagna F, Montagnese S, Ridola L, et al.. The animal naming test: an easy tool for the assessment of hepatic encephalopathy. Hepatology. 2017, 66:198-208. 10.1002\/hep.29146","journal-title":"Hepatology"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.05.011","article-title":"Validation of EncephalApp, smartphone-based Stroop test, for the diagnosis of covert hepatic encephalopathy","volume":"13","author":"Bajaj JS","year":"2015","unstructured":"Bajaj JS, Heuman DM, Sterling RK, et al.. Validation of EncephalApp, smartphone-based Stroop test, for the diagnosis of covert hepatic encephalopathy. Clin Gastroenterol Hepatol. 2015, 13:1828-35.e1. 10.1016\/j.cgh.2014.05.011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.047","article-title":"QuickStroop, a shortened version of EncephalApp, detects covert hepatic encephalopathy with similar accuracy within one minute","volume":"21","author":"Acharya C","year":"2023","unstructured":"Acharya C, Shaw J, Duong N, et al.. QuickStroop, a shortened version of EncephalApp, detects covert hepatic encephalopathy with similar accuracy within one minute. Clin Gastroenterol Hepatol. 2023, 21:136-42. 10.1016\/j.cgh.2021.12.047","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01592.x","article-title":"Neuropsychological tools in hepatology: a survival guide for the clinician","volume":"19","author":"Montagnese S","year":"2012","unstructured":"Montagnese S, Schiff S, De Rui M, Crossey MM, Amodio P, Taylor-Robinson SD. Neuropsychological tools in hepatology: a survival guide for the clinician. J Viral Hepat. 2012, 19:307-15. 10.1111\/j.1365-2893.2012.01592.x","journal-title":"J Viral Hepat"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.04.022","article-title":"Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study","volume":"49","author":"Amodio P","year":"2008","unstructured":"Amodio P, Campagna F, Olianas S, et al.. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol. 2008, 49:346-53. 10.1016\/j.jhep.2008.04.022","journal-title":"J Hepatol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1684-0","article-title":"Validation of the psychometric hepatic encephalopathy score (PHES) for identifying patients with minimal hepatic encephalopathy","volume":"56","author":"Duarte-Rojo A","year":"2011","unstructured":"Duarte-Rojo A, Estradas J, Hern\u00e1ndez-Ramos R, Ponce-de-Le\u00f3n S, C\u00f3rdoba J, Torre A. Validation of the psychometric hepatic encephalopathy score (PHES) for identifying patients with minimal hepatic encephalopathy. Dig Dis Sci. 2011, 56:3014-23. 10.1007\/s10620-011-1684-0","journal-title":"Dig Dis Sci"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2012.07217.x","article-title":"Psychometric hepatic encephalopathy score for the detection of minimal hepatic encephalopathy in Korean patients with liver cirrhosis","volume":"27","author":"Seo YS","year":"2012","unstructured":"Seo YS, Yim SY, Jung JY, et al.. Psychometric hepatic encephalopathy score for the detection of minimal hepatic encephalopathy in Korean patients with liver cirrhosis. J Gastroenterol Hepatol. 2012, 27:1695-704. 10.1111\/j.1440-1746.2012.07217.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i46.8745","article-title":"Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in China","volume":"19","author":"Li SW","year":"2013","unstructured":"Li SW, Wang K, Yu YQ, Wang HB, Li YH, Xu JM. Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in China. World J Gastroenterol. 2013, 19:8745-51. 10.3748\/wjg.v19.i46.8745","journal-title":"World J Gastroenterol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1080\/09084280903297719","article-title":"Factor analysis of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in a large sample of patients suspected of dementia","volume":"17","author":"Schmitt AL","year":"2010","unstructured":"Schmitt AL, Livingston RB, Smernoff EN, Reese EM, Hafer DG, Harris JB. Factor analysis of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in a large sample of patients suspected of dementia. Appl Neuropsychol. 2010, 17:8-17. 10.1080\/09084280903297719","journal-title":"Appl Neuropsychol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.acn.2007.08.008","article-title":"Component structure of the repeatable battery for the assessment of neuropsychological status in dementia","volume":"23","author":"Garcia C","year":"2008","unstructured":"Garcia C, Leahy B, Corradi K, Forchetti C. Component structure of the repeatable battery for the assessment of neuropsychological status in dementia. Arch Clin Neuropsychol. 2008, 23:63-72. 10.1016\/j.acn.2007.08.008","journal-title":"Arch Clin Neuropsychol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1080\/13854040701260370","article-title":"The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): clinical utility in a traumatic brain injury sample","volume":"22","author":"McKay C","year":"2008","unstructured":"McKay C, Wertheimer JC, Fichtenberg NL, Casey JE. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): clinical utility in a traumatic brain injury sample. Clin Neuropsychol. 2008, 22:228-41. 10.1080\/13854040701260370","journal-title":"Clin Neuropsychol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.08.008","article-title":"Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy","volume":"60","author":"Labenz C","year":"2019","unstructured":"Labenz C, Beul L, Toenges G, et al.. Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. Eur J Intern Med. 2019, 60:96-100. 10.1016\/j.ejim.2018.08.008","journal-title":"Eur J Intern Med"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2019.95105","article-title":"Animal Naming Test - a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy","volume":"6","author":"Agarwal A","year":"2020","unstructured":"Agarwal A, Taneja S, Chopra M, Duseja A, Dhiman RK. Animal Naming Test - a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy. Clin Exp Hepatol. 2020, 6:116-24. 10.5114\/ceh.2019.95105","journal-title":"Clin Exp Hepatol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101729","article-title":"Animal naming test for the assessment of minimal hepatic encephalopathy in Asian cirrhotic populations","volume":"45","author":"Qu Y","year":"2021","unstructured":"Qu Y, Li T, Lin C, Liu F, Wu S, Wang L, Ye Q. Animal naming test for the assessment of minimal hepatic encephalopathy in Asian cirrhotic populations. Clin Res Hepatol Gastroenterol. 2021, 45:101729. 10.1016\/j.clinre.2021.101729","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000096","article-title":"Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis","volume":"7","author":"Gairing SJ","year":"2023","unstructured":"Gairing SJ, Schleicher EM, Galle PR, Labenz C. Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis. Hepatol Commun. 2023, 7:10.1097\/HC9.0000000000000096","journal-title":"Hepatol Commun"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185412","article-title":"The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention - a pilot study","volume":"12","author":"Lauridsen MM","year":"2017","unstructured":"Lauridsen MM, Mikkelsen S, Svensson T, et al.. The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention - a pilot study. PLoS One. 2017, 12:e0185412. 10.1371\/journal.pone.0185412","journal-title":"PLoS One"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2012.07.001","article-title":"Inhibitory control test for the detection of minimal hepatic encephalopathy in patients with cirrhosis of liver","volume":"2","author":"Taneja S","year":"2012","unstructured":"Taneja S, Dhiman RK, Khatri A, et al.. Inhibitory control test for the detection of minimal hepatic encephalopathy in patients with cirrhosis of liver. J Clin Exp Hepatol. 2012, 2:306-14. 10.1016\/j.jceh.2012.07.001","journal-title":"J Clin Exp Hepatol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303262","article-title":"Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates","volume":"62","author":"Goldbecker A","year":"2013","unstructured":"Goldbecker A, Weissenborn K, Hamidi Shahrezaei G, et al.. Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut. 2013, 62:1497-504. 10.1136\/gutjnl-2012-303262","journal-title":"Gut"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12248","article-title":"Prospective comparative study of inhibitory control test and psychometric hepatic encephalopathy score for diagnosis and prognosis of minimal hepatic encephalopathy in cirrhotic patients in the Indian subcontinent","volume":"16","author":"Gupta D","year":"2015","unstructured":"Gupta D, Ingle M, Shah K, Phadke A, Sawant P. Prospective comparative study of inhibitory control test and psychometric hepatic encephalopathy score for diagnosis and prognosis of minimal hepatic encephalopathy in cirrhotic patients in the Indian subcontinent. J Dig Dis. 2015, 16:400-7. 10.1111\/1751-2980.12248","journal-title":"J Dig Dis"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_558_19","article-title":"EncephalApp Stroop App predicts poor sleep quality in patients with minimal hepatic encephalopathy due to hepatitis B-induced liver cirrhosis","volume":"26","author":"Luo M","year":"2020","unstructured":"Luo M, Yu XB, Hu SJ, Bai FH. EncephalApp Stroop App predicts poor sleep quality in patients with minimal hepatic encephalopathy due to hepatitis B-induced liver cirrhosis. Saudi J Gastroenterol. 2020, 26:120-8. 10.4103\/sjg.SJG_558_19","journal-title":"Saudi J Gastroenterol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100543","article-title":"EncephalApp Stroop Test validation for the screening of minimal hepatic encephalopathy in Brazil","volume":"27","author":"Cunha-Silva M","year":"2022","unstructured":"Cunha-Silva M, Neto FL, de Ara\u00fajo PS, et al.. EncephalApp Stroop Test validation for the screening of minimal hepatic encephalopathy in Brazil. Ann Hepatol. 2022, 27:100543. 10.1016\/j.aohep.2021.100543","journal-title":"Ann Hepatol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.26574\/maedica.2023.18.1.4","article-title":"Assessment of minimal hepatic encephalopathy with brain MRI and EncephalApp Stroop test","volume":"18","author":"Lupescu IC","year":"2023","unstructured":"Lupescu IC, Iacob S, Lupescu IG, Pietrareanu C, Gheorghe L. Assessment of minimal hepatic encephalopathy with brain MRI and EncephalApp Stroop test. Maedica (Bucur). 2023, 18:4-11. 10.26574\/maedica.2023.18.1.4","journal-title":"Maedica (Bucur)"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.12.020","article-title":"Diagnosis of covert hepatic encephalopathy without specialized tests","volume":"12","author":"Nabi E","year":"2014","unstructured":"Nabi E, Thacker LR, Wade JB, et al.. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin Gastroenterol Hepatol. 2014, 12:1384-9.e2. 10.1016\/j.cgh.2013.12.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.09.028","article-title":"Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial","volume":"14","author":"Maharshi S","year":"2016","unstructured":"Maharshi S, Sharma BC, Sachdeva S, Srivastava S, Sharma P. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol. 2016, 14:454-60. 10.1016\/j.cgh.2015.09.028","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1555","article-title":"Validation of a simple quality-of-life score for identification of minimal and prediction of overt hepatic encephalopathy","volume":"4","author":"Lauridsen MM","year":"2020","unstructured":"Lauridsen MM, Jepsen P, Wernberg CW, Schaffalitzky de Muckadell OB, Bajaj JS, Vilstrup H. Validation of a simple quality-of-life score for identification of minimal and prediction of overt hepatic encephalopathy. Hepatol Commun. 2020, 4:1353-61. 10.1002\/hep4.1555","journal-title":"Hepatol Commun"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2019.18226","article-title":"Advances in psychometric tests for screening minimal hepatic encephalopathy: from paper-and-pencil to computer-aided assessment","volume":"30","author":"Luo M","year":"2019","unstructured":"Luo M, Ma P, Li L, Cao WK. Advances in psychometric tests for screening minimal hepatic encephalopathy: from paper-and-pencil to computer-aided assessment. Turk J Gastroenterol. 2019, 30:398-407. 10.5152\/tjg.2019.18226","journal-title":"Turk J Gastroenterol"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8760(89)90003-2","article-title":"Feedback EEG in the detection of subclinical hepatic encephalopathy: a preliminary report","volume":"8","author":"McLaughlin TJ","year":"1989","unstructured":"McLaughlin TJ, Koff RS. Feedback EEG in the detection of subclinical hepatic encephalopathy: a preliminary report. Int J Psychophysiol. 1989, 8:137-43. 10.1016\/0167-8760(89)90003-2","journal-title":"Int J Psychophysiol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-2457(99)00076-0","article-title":"Spectral versus visual EEG analysis in mild hepatic encephalopathy","volume":"110","author":"Amodio P","year":"1999","unstructured":"Amodio P, Marchetti P, Del Piccolo F, et al.. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol. 1999, 110:1334-44. 10.1016\/S1388-2457(99)00076-0","journal-title":"Clin Neurophysiol"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2006.06.714","article-title":"The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis","volume":"117","author":"Amodio P","year":"2006","unstructured":"Amodio P, Pellegrini A, Ubiali E, et al.. The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. Clin Neurophysiol. 2006, 117:2243-51. 10.1016\/j.clinph.2006.06.714","journal-title":"Clin Neurophysiol"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.10.009","article-title":"Analysis of EEG tracings in frequency and time domain in hepatic encephalopathy","volume":"81","author":"Pascoli D","year":"2006","unstructured":"Pascoli D, Gu\u00e9rit JM, Montagnese S, et al.. Analysis of EEG tracings in frequency and time domain in hepatic encephalopathy. Comput Methods Programs Biomed. 2006, 81:203-12. 10.1016\/j.cmpb.2005.10.009","journal-title":"Comput Methods Programs Biomed"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28477","article-title":"A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy","volume":"63","author":"Schiff S","year":"2016","unstructured":"Schiff S, Casa M, Di Caro V, et al.. A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. Hepatology. 2016, 63:1651-9. 10.1002\/hep.28477","journal-title":"Hepatology"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-005-7921-5","article-title":"Neurophysiological investigation of hepatic encephalopathy","volume":"20","author":"Amodio P","year":"2005","unstructured":"Amodio P, Gatta A. Neurophysiological investigation of hepatic encephalopathy. Metab Brain Dis. 2005, 20:369-79. 10.1007\/s11011-005-7921-5","journal-title":"Metab Brain Dis"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(95)80267-3","article-title":"Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials","volume":"22","author":"Kullmann F","year":"1995","unstructured":"Kullmann F, Hollerbach S, Holstege A, Sch\u00f6lmerich J. Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials. J Hepatol. 1995, 22:101-10. 10.1016\/0168-8278(95)80267-3","journal-title":"J Hepatol"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.3.291","article-title":"Visual evoked potential: a diagnostic tool for the assessment of hepatic encephalopathy","volume":"25","author":"Zeneroli ML","year":"1984","unstructured":"Zeneroli ML, Pinelli G, Gollini G, Penne A, Messori E, Zani G, Ventura E. Visual evoked potential: a diagnostic tool for the assessment of hepatic encephalopathy. Gut. 1984, 25:291-9. 10.1136\/gut.25.3.291","journal-title":"Gut"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.022","article-title":"Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy","volume":"47","author":"Sharma P","year":"2007","unstructured":"Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol. 2007, 47:67-73. 10.1016\/j.jhep.2007.02.022","journal-title":"J Hepatol"},{"key":"ref126","article-title":"Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis","volume":"9","author":"Sharma P","year":"2010","unstructured":"Sharma P, Sharma BC, Sarin SK. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. Hepatobiliary Pancreat Dis Int. 2010, 9:27-32.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-011-9242-1","article-title":"Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease","volume":"26","author":"Lauridsen MM","year":"2011","unstructured":"Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. Metab Brain Dis. 2011, 26:135-9. 10.1007\/s11011-011-9242-1","journal-title":"Metab Brain Dis"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.01.133","article-title":"Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis","volume":"50","author":"Barone M","year":"2018","unstructured":"Barone M, Shahini E, Iannone A, Viggiani MT, Corvace V, Principi M, Di Leo A. Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis. Dig Liver Dis. 2018, 50:496-500. 10.1016\/j.dld.2018.01.133","journal-title":"Dig Liver Dis"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1159\/000375350","article-title":"Diagnosis and treatment of low-grade hepatic encephalopathy","volume":"33","author":"Direkze S","year":"2015","unstructured":"Direkze S, Jalan R. Diagnosis and treatment of low-grade hepatic encephalopathy. Dig Dis. 2015, 33:562-9. 10.1159\/000375350","journal-title":"Dig Dis"},{"key":"ref130","doi-asserted-by":"crossref","DOI":"10.15761\/BRCP.1000117","article-title":"Predictive biomarkers for diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis: a preliminary result in a single center study in Japan","volume":"1","author":"Suzuki K","year":"2016","unstructured":"Suzuki K, Kuroda H, Sawara K, et al.. Predictive biomarkers for diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis: a preliminary result in a single center study in Japan. Biomed Res Clin Prac. 2016, 1:","journal-title":"Biomed Res Clin Prac"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14408","article-title":"Mechanistic insight, diagnosis, and treatment of ammonia-induced hepatic encephalopathy","volume":"34","author":"Fiati Kenston SS","year":"2019","unstructured":"Fiati Kenston SS, Song X, Li Z, Zhao J. Mechanistic insight, diagnosis, and treatment of ammonia-induced hepatic encephalopathy. J Gastroenterol Hepatol. 2019, 34:31-9. 10.1111\/jgh.14408","journal-title":"J Gastroenterol Hepatol"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.123","article-title":"3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis","volume":"106","author":"Montoliu C","year":"2011","unstructured":"Montoliu C, Cauli O, Urios A, et al.. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol. 2011, 106:1629-37. 10.1038\/ajg.2011.123","journal-title":"Am J Gastroenterol"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2021.109292","article-title":"Evaluation of different diagnostic modalities of minimal hepatic encephalopathy in cirrhotic patients: case-control study","volume":"7","author":"Salman T","year":"2021","unstructured":"Salman T, Elsabaawy M, Omar M, et al.. Evaluation of different diagnostic modalities of minimal hepatic encephalopathy in cirrhotic patients: case-control study. Clin Exp Hepatol. 2021, 7:312-9. 10.5114\/ceh.2021.109292","journal-title":"Clin Exp Hepatol"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020519","article-title":"Psychometric hepatic encephalopathy score for the diagnosis of minimal hepatic encephalopathy in Thai cirrhotic patients","volume":"12","author":"Thanapirom K","year":"2023","unstructured":"Thanapirom K, Wongwandee M, Suksawatamnuay S, et al.. Psychometric hepatic encephalopathy score for the diagnosis of minimal hepatic encephalopathy in Thai cirrhotic patients. J Clin Med. 2023, 12:10.3390\/jcm12020519","journal-title":"J Clin Med"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02009.x","article-title":"Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines","volume":"29","author":"Randolph C","year":"2009","unstructured":"Randolph C, Hilsabeck R, Kato A, et al.. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009, 29:629-35. 10.1111\/j.1478-3231.2009.02009.x","journal-title":"Liver Int"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup H","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al.. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014, 60:715-35. 10.1002\/hep.27210","journal-title":"Hepatology"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1988.tb00252.x","article-title":"Impact of cirrhosis on the neuropsychological test performance of alcoholics","volume":"12","author":"Tarter RE","year":"1988","unstructured":"Tarter RE, Van Thiel DH, Arria AM, Carra J, Moss H. Impact of cirrhosis on the neuropsychological test performance of alcoholics. Alcohol Clin Exp Res. 1988, 12:619-21. 10.1111\/j.1530-0277.1988.tb00252.x","journal-title":"Alcohol Clin Exp Res"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2006.01483.x","article-title":"Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation","volume":"60","author":"Sorrell JH","year":"2006","unstructured":"Sorrell JH, Zolnikov BJ, Sharma A, Jinnai I. Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci. 2006, 60:174-81. 10.1111\/j.1440-1819.2006.01483.x","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.04.036","article-title":"Changing epidemiology of cirrhosis and hepatic encephalopathy","volume":"20","author":"Louissaint J","year":"2022","unstructured":"Louissaint J, Deutsch-Link S, Tapper EB. Changing epidemiology of cirrhosis and hepatic encephalopathy. Clin Gastroenterol Hepatol. 2022, 20:S1-8. 10.1016\/j.cgh.2022.04.036","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-012-9318-6","article-title":"Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis","volume":"27","author":"Lauridsen MM","year":"2012","unstructured":"Lauridsen MM, Gr\u00f8nb\u00e6k H, N\u00e6ser EB, Leth ST, Vilstrup H. Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis. Metab Brain Dis. 2012, 27:559-65. 10.1007\/s11011-012-9318-6","journal-title":"Metab Brain Dis"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2017.00037","article-title":"Minimal hepatic encephalopathy in Indians: psychometric hepatic encephalopathy score and inhibitory control test for diagnosis and rifaximin or lactulose for its reversal","volume":"7","author":"Pawar VB","year":"2019","unstructured":"Pawar VB, Surude RG, Sonthalia N, Zanwar V, Jain S, Contractor Q, Rathi PM. Minimal hepatic encephalopathy in Indians: psychometric hepatic encephalopathy score and inhibitory control test for diagnosis and rifaximin or lactulose for its reversal. J Clin Transl Hepatol. 2019, 7:304-12. 10.14218\/JCTH.2017.00037","journal-title":"J Clin Transl Hepatol"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01048.x","article-title":"Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy","volume":"102","author":"Bajaj JS","year":"2007","unstructured":"Bajaj JS, Saeian K, Verber MD, et al.. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol. 2007, 102:754-60. 10.1111\/j.1572-0241.2007.01048.x","journal-title":"Am J Gastroenterol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.021","article-title":"Inhibitory control test for the diagnosis of minimal hepatic encephalopathy","volume":"135","author":"Bajaj JS","year":"2008","unstructured":"Bajaj JS, Hafeezullah M, Franco J, et al.. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology. 2008, 135:1591-600. 10.1053\/j.gastro.2008.07.021","journal-title":"Gastroenterology"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.057","article-title":"Improving the inhibitory control task to detect minimal hepatic encephalopathy","volume":"139","author":"Amodio P","year":"2010","unstructured":"Amodio P, Ridola L, Schiff S, et al.. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology. 2010, 139:510-8. 10.1053\/j.gastro.2010.04.057","journal-title":"Gastroenterology"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26309","article-title":"The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy","volume":"58","author":"Bajaj JS","year":"2013","unstructured":"Bajaj JS, Thacker LR, Heuman DM, et al.. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013, 58:1122-32. 10.1002\/hep.26309","journal-title":"Hepatology"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.377","article-title":"Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: a multicenter US-based, norm-based study","volume":"111","author":"Allampati S","year":"2016","unstructured":"Allampati S, Duarte-Rojo A, Thacker LR, et al.. Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: a multicenter US-based, norm-based study. Am J Gastroenterol. 2016, 111:78-86. 10.1038\/ajg.2015.377","journal-title":"Am J Gastroenterol"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.09.024","article-title":"QuickStroop predicts time to development of overt hepatic encephalopathy and related hospitalizations in patients with cirrhosis","volume":"22","author":"Kanagalingam G","year":"2024","unstructured":"Kanagalingam G, Park D, Badal BD, Fagan A, Thacker LR, Bajaj JS. QuickStroop predicts time to development of overt hepatic encephalopathy and related hospitalizations in patients with cirrhosis. Clin Gastroenterol Hepatol. 2024, 22:899-901. 10.1016\/j.cgh.2023.09.024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290619","article-title":"Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests","volume":"29","author":"Amodio P","year":"1999","unstructured":"Amodio P, Del Piccolo F, Marchetti P, et al.. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999, 29:1662-7. 10.1002\/hep.510290619","journal-title":"Hepatology"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-5728(98)00051-4","article-title":"Catecholamines and lipopolysaccharide synergistically induce the release of interleukin-6 from thymic epithelial cells","volume":"86","author":"von Patay B","year":"1998","unstructured":"von Patay B, Loppnow H, Feindt J, Kurz B, Mentlein R. Catecholamines and lipopolysaccharide synergistically induce the release of interleukin-6 from thymic epithelial cells. J Neuroimmunol. 1998, 86:182-9. 10.1016\/s0165-5728(98)00051-4","journal-title":"J Neuroimmunol"},{"key":"ref150","article-title":"Continuous EEG monitoring in the intensive care unit: an overview","volume":"21","author":"Hirsch LJ","year":"2004","unstructured":"Hirsch LJ. Continuous EEG monitoring in the intensive care unit: an overview. J Clin Neurophysiol. 2004, 21:332-40.","journal-title":"J Clin Neurophysiol"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2013.06.003","article-title":"Impaired evoked and resting-state brain oscillations in patients with liver cirrhosis as revealed by magnetoencephalography","volume":"2","author":"G\u00f6tz T","year":"2013","unstructured":"G\u00f6tz T, Huonker R, Kranczioch C, Reuken P, Witte OW, G\u00fcnther A, Debener S. Impaired evoked and resting-state brain oscillations in patients with liver cirrhosis as revealed by magnetoencephalography. Neuroimage Clin. 2013, 2:873-82. 10.1016\/j.nicl.2013.06.003","journal-title":"Neuroimage Clin"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(57)90005-3","article-title":"The electroencephalograph in liver disease","volume":"273","author":"Parsons-Smith BG","year":"1957","unstructured":"Parsons-Smith BG, Summerskill WH, Dawson AM, Sherlock S. The electroencephalograph in liver disease. Lancet. 1957, 273:867-71. 10.1016\/S0140-6736(57)90005-3","journal-title":"Lancet"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02030.x","article-title":"Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines","volume":"29","author":"Guerit JM","year":"2009","unstructured":"Guerit JM, Amantini A, Fischer C, et al.. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009, 29:789-96. 10.1111\/j.1478-3231.2009.02030.x","journal-title":"Liver Int"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00129-5","article-title":"Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients","volume":"35","author":"Amodio P","year":"2001","unstructured":"Amodio P, Del Piccolo F, Petten\u00f2 E, et al.. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001, 35:37-45. 10.1016\/S0168-8278(01)00129-5","journal-title":"J Hepatol"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.085","article-title":"Electroencephalography in patients with cirrhosis","volume":"141","author":"Marchetti P","year":"2011","unstructured":"Marchetti P, D'Avanzo C, Orsato R, et al.. Electroencephalography in patients with cirrhosis. Gastroenterology. 2011, 141:1680-9. 10.1053\/j.gastro.2011.06.085","journal-title":"Gastroenterology"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2024.103918","article-title":"A neural mass model for disturbance of alpha rhythm in the minimal hepatic encephalopathy","volume":"128","author":"Song J","year":"2024","unstructured":"Song J, Westover MB, Zhang R. A neural mass model for disturbance of alpha rhythm in the minimal hepatic encephalopathy. Mol Cell Neurosci. 2024, 128:103918. 10.1016\/j.mcn.2024.103918","journal-title":"Mol Cell Neurosci"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50406","article-title":"T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities","volume":"38","author":"C\u00f3rdoba J","year":"2003","unstructured":"C\u00f3rdoba J, Raguer N, Flavi\u00e0 M, Vargas V, Jacas C, Alonso J, Rovira A. T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology. 2003, 38:1026-33. 10.1053\/jhep.2003.50406","journal-title":"Hepatology"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-006-9036-z","article-title":"Functional abnormalities of the motor tract in the rat after portocaval anastomosis and after carbon tetrachloride induction of cirrhosis","volume":"21","author":"Oria M","year":"2006","unstructured":"Oria M, Raguer N, Chatauret N, Bartol\u00ed R, Odena G, Planas R, C\u00f3rdoba J. Functional abnormalities of the motor tract in the rat after portocaval anastomosis and after carbon tetrachloride induction of cirrhosis. Metab Brain Dis. 2006, 21:297-308. 10.1007\/s11011-006-9036-z","journal-title":"Metab Brain Dis"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080519","article-title":"Assessment of hepatic encephalopathy with visual evoked potentials compared with conventional methods","volume":"8","author":"Sandford NL","year":"1988","unstructured":"Sandford NL, Saul RE. Assessment of hepatic encephalopathy with visual evoked potentials compared with conventional methods. Hepatology. 1988, 8:1094-8. 10.1002\/hep.1840080519","journal-title":"Hepatology"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2002.01431.x","article-title":"Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy","volume":"22","author":"Saxena N","year":"2002","unstructured":"Saxena N, Bhatia M, Joshi YK, Garg PK, Dwivedi SN, Tandon RK. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver. 2002, 22:190-7. 10.1034\/j.1600-0676.2002.01431.x","journal-title":"Liver"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840120412","article-title":"The auditory P300 event-related potential: an objective marker of the encephalopathy of chronic liver disease","volume":"12","author":"Davies MG","year":"1990","unstructured":"Davies MG, Rowan MJ, MacMathuna P, Keeling PW, Weir DG, Feely J. The auditory P300 event-related potential: an objective marker of the encephalopathy of chronic liver disease. Hepatology. 1990, 12:688-94. 10.1002\/hep.1840120412","journal-title":"Hepatology"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(200003)15:2<103::AID-HUP149>3.0.CO;2-7","article-title":"Critical flicker fusion threshold: a potentially useful measure for the early detection of Alzheimer's disease","volume":"15","author":"Curran S","year":"2000","unstructured":"Curran S, Wattis J. Critical flicker fusion threshold: a potentially useful measure for the early detection of Alzheimer's disease. Hum Psychopharmacol. 2000, 15:103-12. 10.1002\/(SICI)1099-1077(200003)15:2&lt;103::AID-HUP149&gt;3.0.CO;2-7","journal-title":"Hum Psychopharmacol"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04130.x","article-title":"Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy","volume":"96","author":"Romero-G\u00f3mez M","year":"2001","unstructured":"Romero-G\u00f3mez M, Boza F, Garc\u00eda-Valdecasas MS, Garc\u00eda E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001, 96:2718-23. 10.1111\/j.1572-0241.2001.04130.x","journal-title":"Am J Gastroenterol"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.12.030","article-title":"Clinical significance of extrapyramidal signs in patients with cirrhosis","volume":"42","author":"Jover R","year":"2005","unstructured":"Jover R, Compa\u00f1y L, Guti\u00e9rrez A, et al.. Clinical significance of extrapyramidal signs in patients with cirrhosis. J Hepatol. 2005, 42:659-65. 10.1016\/j.jhep.2004.12.030","journal-title":"J Hepatol"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.3152","article-title":"Adherence to recommended inpatient hepatic encephalopathy workup","volume":"14","author":"Kumral D","year":"2019","unstructured":"Kumral D, Qayyum R, Roseff S, Sterling RK, Siddiqui MS. Adherence to recommended inpatient hepatic encephalopathy workup. J Hosp Med. 2019, 14:157-60. 10.12788\/jhm.3152","journal-title":"J Hosp Med"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-008-9115-4","article-title":"Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy","volume":"24","author":"Cauli O","year":"2009","unstructured":"Cauli O, Rodrigo R, Llansola M, et al.. Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy. Metab Brain Dis. 2009, 24:69-80. 10.1007\/s11011-008-9115-4","journal-title":"Metab Brain Dis"},{"key":"ref167","article-title":"3-Nitrotyrosine as a biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis","volume":"72","author":"Awad EA","year":"2018","unstructured":"Awad EA, Mohammed MN, Sayyed MM, El-Khayal AES, Ahmed MAS. 3-Nitrotyrosine as a biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Egypt J Hosp Med. 2018, 72:5647.","journal-title":"Egypt J Hosp Med"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.00790.x","article-title":"Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis","volume":"94","author":"Genesca J","year":"1999","unstructured":"Genesca J, Gonzalez A, Segura R, et al.. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol. 1999, 94:169-77. 10.1111\/j.1572-0241.1999.00790.x","journal-title":"Am J Gastroenterol"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.28742","article-title":"S-100b and neuron-specific enolase in patients with fulminant hepatic failure","volume":"7","author":"Strauss GI","year":"2001","unstructured":"Strauss GI, Christiansen M, M\u00f8ller K, Clemmesen JO, Larsen FS, Knudsen GM. S-100b and neuron-specific enolase in patients with fulminant hepatic failure. Liver Transpl. 2001, 7:964-70. 10.1053\/jlts.2001.28742","journal-title":"Liver Transpl"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50172","article-title":"Serum protein S-100b in acute liver failure: results of the US Acute Liver Failure Study group","volume":"9","author":"Vaquero J","year":"2003","unstructured":"Vaquero J, Jordano Q, Lee WM, Blei AT. Serum protein S-100b in acute liver failure: results of the US Acute Liver Failure Study group. Liver Transpl. 2003, 9:887-8. 10.1053\/jlts.2003.50172","journal-title":"Liver Transpl"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01604.x","article-title":"Serum S100b (astrocyte-specific protein) is a useful marker of hepatic encephalopathy in patients with fulminant hepatitis","volume":"28","author":"Isobe-Harima Y","year":"2008","unstructured":"Isobe-Harima Y, Terai S, Segawa M, Uchida K, Yamasaki T, Sakaida I. Serum S100b (astrocyte-specific protein) is a useful marker of hepatic encephalopathy in patients with fulminant hepatitis. Liver Int. 2008, 28:146-7. 10.1111\/j.1478-3231.2007.01604.x","journal-title":"Liver Int"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i17.4397","article-title":"Clinical scenarios for the use of S100\u03b2 as a marker of hepatic encephalopathy","volume":"22","author":"Duarte-Rojo A","year":"2016","unstructured":"Duarte-Rojo A, Ruiz-Marg\u00e1in A, Macias-Rodriguez RU, Cubero FJ, Estradas-Trujillo J, Mu\u00f1oz-Fuentes RM, Torre A. Clinical scenarios for the use of S100\u03b2 as a marker of hepatic encephalopathy. World J Gastroenterol. 2016, 22:4397-402. 10.3748\/wjg.v22.i17.4397","journal-title":"World J Gastroenterol"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1023\/a:1020785009005","article-title":"Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy","volume":"14","author":"Wiltfang J","year":"1999","unstructured":"Wiltfang J, Nolte W, Otto M, et al.. Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. Metab Brain Dis. 1999, 14:239-51. 10.1023\/a:1020785009005","journal-title":"Metab Brain Dis"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.293","article-title":"Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis","volume":"104","author":"Guevara M","year":"2009","unstructured":"Guevara M, Baccaro ME, Torre A, et al.. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009, 104:1382-9. 10.1038\/ajg.2009.293","journal-title":"Am J Gastroenterol"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.07.007","article-title":"Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients","volume":"63","author":"Jepsen P","year":"2015","unstructured":"Jepsen P, Watson H, Andersen PK, Vilstrup H. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. J Hepatol. 2015, 63:1133-8. 10.1016\/j.jhep.2015.07.007","journal-title":"J Hepatol"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4363","article-title":"Precipitating factors and treatment outcomes of hepatic encephalopathy in liver cirrhosis","volume":"11","author":"Poudyal NS","year":"2019","unstructured":"Poudyal NS, Chaudhary S, Kc S, et al.. Precipitating factors and treatment outcomes of hepatic encephalopathy in liver cirrhosis. Cureus. 2019, 11:e4363. 10.7759\/cureus.4363","journal-title":"Cureus"},{"key":"ref177","doi-asserted-by":"crossref","DOI":"10.1186\/s43066-023-00247-x","article-title":"Prediction of hepatic decompensation and hepatocellular carcinoma after direct-acting antiviral therapy in patients with hepatitis C-related liver cirrhosis: a cohort study","volume":"13","author":"Marie MS","year":"2023","unstructured":"Marie MS, Shousha HI, Abdelrazek W, et al.. Prediction of hepatic decompensation and hepatocellular carcinoma after direct-acting antiviral therapy in patients with hepatitis C-related liver cirrhosis: a cohort study. Egypt Liver J. 2023, 13:12.","journal-title":"Egypt Liver J"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.12.021","article-title":"Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis","volume":"72","author":"Praktiknjo M","year":"2020","unstructured":"Praktiknjo M, Sim\u00f3n-Talero M, R\u00f6mer J, et al.. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. J Hepatol. 2020, 72:1140-50. 10.1016\/j.jhep.2019.12.021","journal-title":"J Hepatol"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001164","article-title":"Development and validation of a clinical-genetic risk score to predict hepatic encephalopathy in patients with liver cirrhosis","volume":"116","author":"Gil-G\u00f3mez A","year":"2021","unstructured":"Gil-G\u00f3mez A, Ampuero J, Rojas \u00c1, et al.. Development and validation of a clinical-genetic risk score to predict hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol. 2021, 116:1238-47. 10.14309\/ajg.0000000000001164","journal-title":"Am J Gastroenterol"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16671286","article-title":"Covered versus bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials","volume":"10","author":"Qi X","year":"2017","unstructured":"Qi X, Tian Y, Zhang W, Yang Z, Guo X. Covered versus bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials. Ther Adv Gastroenterol. 2017, 10:32-41. 10.1177\/1756283X16671286","journal-title":"Ther Adv Gastroenterol"},{"key":"ref181","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i42.15756","article-title":"Covert hepatic encephalopathy: agreement and predictive validity of different indices","volume":"20","author":"Montagnese S","year":"2014","unstructured":"Montagnese S, Balistreri E, Schiff S, et al.. Covert hepatic encephalopathy: agreement and predictive validity of different indices. World J Gastroenterol. 2014, 20:15756-62. 10.3748\/wjg.v20.i42.15756","journal-title":"World J Gastroenterol"},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.5114\/pg.2021.111389","article-title":"Minimal hepatic encephalopathy - diagnosis and treatment","volume":"16","author":"Pisarek W","year":"2021","unstructured":"Pisarek W. Minimal hepatic encephalopathy - diagnosis and treatment. Prz Gastroenterol. 2021, 16:311-7. 10.5114\/pg.2021.111389","journal-title":"Prz Gastroenterol"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21515","article-title":"Testing for minimal hepatic encephalopathy in the United States: an AASLD survey","volume":"45","author":"Bajaj JS","year":"2007","unstructured":"Bajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the United States: an AASLD survey. Hepatology. 2007, 45:833-4. 10.1002\/hep.21515","journal-title":"Hepatology"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.013","article-title":"Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy","volume":"73","author":"Rose CF","year":"2020","unstructured":"Rose CF, Amodio P, Bajaj JS, et al.. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol. 2020, 73:1526-47. 10.1016\/j.jhep.2020.07.013","journal-title":"J Hepatol"},{"key":"ref185","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.06.039","article-title":"Covert and overt hepatic encephalopathy: diagnosis and management","volume":"13","author":"Patidar KR","year":"2015","unstructured":"Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015, 13:2048-61. 10.1016\/j.cgh.2015.06.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref186","doi-asserted-by":"publisher","DOI":"10.1111\/j.1746-6342.2006.03218.x","article-title":"Review article: the current pharmacological therapies for hepatic encephalopathy","volume":"25","author":"Bass NM","year":"2007","unstructured":"Bass NM. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther. 2007, 25:23-31. 10.1111\/j.1746-6342.2006.03218.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref187","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(89)90009-3","article-title":"Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients: a randomised, cross-over study","volume":"8","author":"Morgan MY","year":"1989","unstructured":"Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients: a randomised, cross-over study. J Hepatol. 1989, 8:208-17. 10.1016\/0168-8278(89)90009-3","journal-title":"J Hepatol"},{"key":"ref188","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.118289000.x","article-title":"Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy","volume":"11","author":"Horsmans Y","year":"1997","unstructured":"Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther. 1997, 11:165-70. 10.1046\/j.1365-2036.1997.118289000.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref189","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.1997.v26.pm0009397979","article-title":"Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy","volume":"26","author":"Watanabe A","year":"1997","unstructured":"Watanabe A, Sakai T, Sato S, et al.. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology. 1997, 26:1410-4. 10.1053\/jhep.1997.v26.pm0009397979","journal-title":"Hepatology"},{"key":"ref190","doi-asserted-by":"publisher","DOI":"10.1023\/a:1005556826152","article-title":"Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy","volume":"45","author":"Dhiman RK","year":"2000","unstructured":"Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci. 2000, 45:1549-52. 10.1023\/a:1005556826152","journal-title":"Dig Dis Sci"},{"key":"ref191","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21533","article-title":"Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy","volume":"45","author":"Prasad S","year":"2007","unstructured":"Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007, 45:549-59. 10.1002\/hep.21533","journal-title":"Hepatology"},{"key":"ref192","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-012-9303-0","article-title":"A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy","volume":"27","author":"Bajaj JS","year":"2012","unstructured":"Bajaj JS, Gillevet PM, Patel NR, et al.. A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. Metab Brain Dis. 2012, 27:205-15. 10.1007\/s11011-012-9303-0","journal-title":"Metab Brain Dis"},{"key":"ref193","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2012.07186.x","article-title":"Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose","volume":"27","author":"Sharma P","year":"2012","unstructured":"Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2012, 27:1329-35. 10.1111\/j.1440-1746.2012.07186.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref194","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajg.2013.08.002","article-title":"Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy","volume":"14","author":"Ziada DH","year":"2013","unstructured":"Ziada DH, Soliman HH, El Yamany SA, Hamisa MF, Hasan AM. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab J Gastroenterol. 2013, 14:116-22. 10.1016\/j.ajg.2013.08.002","journal-title":"Arab J Gastroenterol"},{"key":"ref195","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12429","article-title":"Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial","volume":"45","author":"Pratap Mouli V","year":"2015","unstructured":"Pratap Mouli V, Benjamin J, Bhushan Singh M, Mani K, Garg SK, Saraya A, Joshi YK. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatol Res. 2015, 45:880-9. 10.1111\/hepr.12429","journal-title":"Hepatol Res"},{"key":"ref196","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12921","article-title":"Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy","volume":"36","author":"Sidhu SS","year":"2016","unstructured":"Sidhu SS, Goyal O, Parker RA, Kishore H, Sood A. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver Int. 2016, 36:378-85. 10.1111\/liv.12921","journal-title":"Liver Int"},{"key":"ref197","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12816","article-title":"Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial","volume":"20","author":"Wang JY","year":"2019","unstructured":"Wang JY, Bajaj JS, Wang JB, et al.. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial. J Dig Dis. 2019, 20:547-56. 10.1111\/1751-2980.12816","journal-title":"J Dig Dis"},{"key":"ref198","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1091167","article-title":"Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota","volume":"14","author":"Wang MW","year":"2023","unstructured":"Wang MW, Ma WJ, Wang Y, Ma XH, Xue YF, Guan J, Chen X. Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota. Front Microbiol. 2023, 14:1091167. 10.3389\/fmicb.2023.1091167","journal-title":"Front Microbiol"},{"key":"ref199","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.455","article-title":"Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)","volume":"106","author":"Sidhu SS","year":"2011","unstructured":"Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol. 2011, 106:307-16. 10.1038\/ajg.2010.455","journal-title":"Am J Gastroenterol"},{"key":"ref200","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06416-z","article-title":"Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy","volume":"12","author":"Ballester MP","year":"2022","unstructured":"Ballester MP, Gallego JJ, Fiorillo A, et al.. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. Sci Rep. 2022, 12:2463. 10.1038\/s41598-022-06416-z","journal-title":"Sci Rep"},{"key":"ref201","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"Bajaj JS","year":"2013","unstructured":"Bajaj JS, Heuman DM, Sanyal AJ, et al.. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013, 8:e60042. 10.1371\/journal.pone.0060042","journal-title":"PLoS One"},{"key":"ref202","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-014-9507-6","article-title":"Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with rifaximin in cirrhosis: implications for the gut-liver-brain axis","volume":"29","author":"Ahluwalia V","year":"2014","unstructured":"Ahluwalia V, Wade JB, Heuman DM, et al.. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with rifaximin in cirrhosis: implications for the gut-liver-brain axis. Metab Brain Dis. 2014, 29:1017-25. 10.1007\/s11011-014-9507-6","journal-title":"Metab Brain Dis"},{"key":"ref203","article-title":"Proposed management protocol for ingested esophageal foreign body and aortoesophageal fistula: a single-center experience","volume":"8","author":"Wei Y","year":"2015","unstructured":"Wei Y, Chen L, Wang Y, Yu D, Peng J, Xu J. Proposed management protocol for ingested esophageal foreign body and aortoesophageal fistula: a single-center experience. Int J Clin Exp Med. 2015, 8:607-15.","journal-title":"Int J Clin Exp Med"},{"key":"ref204","doi-asserted-by":"publisher","DOI":"10.5604\/16652681.1226822","article-title":"\u00a0Minimal hepatic encephalopathy in cirrhosis - how long to treat?","volume":"16","author":"Goyal O","year":"2017","unstructured":"Goyal O, Sidhu SS, Kishore H. \u00a0Minimal hepatic encephalopathy in cirrhosis - how long to treat?. Ann Hepatol. 2017, 16:115-22. 10.5604\/16652681.1226822","journal-title":"Ann Hepatol"},{"key":"ref205","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13203239","article-title":"Comparative analysis of the efficacy of different regimens of 12 months rifaximin-alfa therapy in patients with liver cirrhosis and minimal hepatic encephalopathy","volume":"13","author":"Bakulin IG","year":"2023","unstructured":"Bakulin IG, Ivanova KN, Eremina EY, Marchenko NV. Comparative analysis of the efficacy of different regimens of 12 months rifaximin-alfa therapy in patients with liver cirrhosis and minimal hepatic encephalopathy. Diagnostics (Basel). 2023, 13:10.3390\/diagnostics13203239","journal-title":"Diagnostics (Basel)"},{"key":"ref206","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914727","article-title":"Neurofilament light chain protein in plasma and extracellular vesicles is associated with minimal hepatic encephalopathy and responses to rifaximin treatment in cirrhotic patients","volume":"24","author":"Fiorillo A","year":"2023","unstructured":"Fiorillo A, Gallego JJ, Casanova-Ferrer F, et al.. Neurofilament light chain protein in plasma and extracellular vesicles is associated with minimal hepatic encephalopathy and responses to rifaximin treatment in cirrhotic patients. Int J Mol Sci. 2023, 24:10.3390\/ijms241914727","journal-title":"Int J Mol Sci"},{"key":"ref207","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04844-7","article-title":"Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity","volume":"22","author":"Casanova-Ferrer F","year":"2024","unstructured":"Casanova-Ferrer F, Gallego JJ, Fiorillo A, et al.. Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity. J Transl Med. 2024, 22:49. 10.1186\/s12967-023-04844-7","journal-title":"J Transl Med"},{"key":"ref208","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(85)80004-4","article-title":"Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double-blind placebo-controlled crossover study","volume":"88","author":"Egberts EH","year":"1985","unstructured":"Egberts EH, Schomerus H, Hamster W, J\u00fcrgens P. Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double-blind placebo-controlled crossover study. Gastroenterology. 1985, 88:887-95. 10.1016\/s0016-5085(85)80004-4","journal-title":"Gastroenterology"},{"key":"ref209","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(05)80210-7","article-title":"Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study","volume":"17","author":"Plauth M","year":"1993","unstructured":"Plauth M, Egberts EH, Hamster W, et al.. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study. J Hepatol. 1993, 17:308-14. 10.1016\/s0168-8278(05)80210-7","journal-title":"J Hepatol"},{"key":"ref210","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(03)00323-8","article-title":"Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial","volume":"124","author":"Marchesini G","year":"2003","unstructured":"Marchesini G, Bianchi G, Merli M, et al.. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003, 124:1792-801. 10.1016\/s0016-5085(03)00323-8","journal-title":"Gastroenterology"},{"key":"ref211","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.9","article-title":"Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study","volume":"106","author":"Les I","year":"2011","unstructured":"Les I, Doval E, Garc\u00eda-Mart\u00ednez R, et al.. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011, 106:1081-8. 10.1038\/ajg.2011.9","journal-title":"Am J Gastroenterol"},{"key":"ref212","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9687-y","article-title":"Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study","volume":"52","author":"Malaguarnera M","year":"2007","unstructured":"Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2007, 52:3259-65. 10.1007\/s10620-006-9687-y","journal-title":"Dig Dis Sci"},{"key":"ref213","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01861.x","article-title":"Probiotic yogurt for the treatment of minimal hepatic encephalopathy","volume":"103","author":"Bajaj JS","year":"2008","unstructured":"Bajaj JS, Saeian K, Christensen KM, et al.. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008, 103:1707-15. 10.1111\/j.1572-0241.2008.01861.x","journal-title":"Am J Gastroenterol"},{"key":"ref214","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3282f3e6f5","article-title":"An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy","volume":"20","author":"Sharma P","year":"2008","unstructured":"Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2008, 20:506-11. 10.1097\/MEG.0b013e3282f3e6f5","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref215","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32834696f5","article-title":"A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy","volume":"23","author":"Mittal VV","year":"2011","unstructured":"Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011, 23:725-32. 10.1097\/MEG.0b013e32834696f5","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref216","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12695","article-title":"Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis","volume":"39","author":"Bajaj JS","year":"2014","unstructured":"Bajaj JS, Heuman DM, Hylemon PB, et al.. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 2014, 39:1113-25. 10.1111\/apt.12695","journal-title":"Aliment Pharmacol Ther"},{"key":"ref217","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.11.006","article-title":"Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial","volume":"12","author":"Lunia MK","year":"2014","unstructured":"Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol. 2014, 12:1003-8.e1. 10.1016\/j.cgh.2013.11.006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref218","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.136975","article-title":"Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial","volume":"20","author":"Sharma K","year":"2014","unstructured":"Sharma K, Pant S, Misra S, et al.. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol. 2014, 20:225-32. 10.4103\/1319-3767.136975","journal-title":"Saudi J Gastroenterol"},{"key":"ref219","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518776064","article-title":"Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis","volume":"46","author":"Xia X","year":"2018","unstructured":"Xia X, Chen J, Xia J, et al.. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res. 2018, 46:3596-604. 10.1177\/0300060518776064","journal-title":"J Int Med Res"},{"key":"ref220","article-title":"Can contrast-enhanced renal MR angiography replace conventional angiography in preoperative evaluation of living renal donors?","volume":"22","author":"Emam AT","year":"2011","unstructured":"Emam AT, Aloraifi IA, Egail SA. Can contrast-enhanced renal MR angiography replace conventional angiography in preoperative evaluation of living renal donors?. Saudi J Kidney Dis Transpl. 2011, 22:225-31.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref221","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.01092.x","article-title":"Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: a preliminary, prospective, open-label study","volume":"43","author":"Kato A","year":"2013","unstructured":"Kato A, Tanaka H, Kawaguchi T, et al.. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: a preliminary, prospective, open-label study. Hepatol Res. 2013, 43:452-8. 10.1111\/j.1872-034X.2012.01092.x","journal-title":"Hepatol Res"},{"key":"ref222","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.38","article-title":"Reversal of low-grade cerebral edema after lactulose\/rifaximin therapy in patients with cirrhosis and minimal hepatic encephalopathy","volume":"6","author":"Rai R","year":"2015","unstructured":"Rai R, Ahuja CK, Agrawal S, et al.. Reversal of low-grade cerebral edema after lactulose\/rifaximin therapy in patients with cirrhosis and minimal hepatic encephalopathy. Clin Transl Gastroenterol. 2015, 6:e111. 10.1038\/ctg.2015.38","journal-title":"Clin Transl Gastroenterol"},{"key":"ref223","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002567","article-title":"Clinical study of probiotics combined with lactulose for minimal hepatic encephalopathy treatment","volume":"35","author":"Shi J","year":"2023","unstructured":"Shi J, Li F. Clinical study of probiotics combined with lactulose for minimal hepatic encephalopathy treatment. Eur J Gastroenterol Hepatol. 2023, 35:777-81. 10.1097\/MEG.0000000000002567","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref224","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0238-6","article-title":"Acetyl-L-carnitine treatment in minimal hepatic encephalopathy","volume":"53","author":"Malaguarnera M","year":"2008","unstructured":"Malaguarnera M, Gargante MP, Cristaldi E, et al.. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci. 2008, 53:3018-25. 10.1007\/s10620-008-0238-6","journal-title":"Dig Dis Sci"},{"key":"ref225","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-011-0087-7","article-title":"Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication","volume":"30","author":"Agrawal A","year":"2011","unstructured":"Agrawal A, Gupta A, Chandra M, Koowar S. Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. Indian J Gastroenterol. 2011, 30:29-32. 10.1007\/s12664-011-0087-7","journal-title":"Indian J Gastroenterol"},{"key":"ref226","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32835afaa5","article-title":"Treatment with a potassium-iron-phosphate-citrate complex improves PSE scores and quality of life in patients with minimal hepatic encephalopathy: a multicenter, randomized, placebo-controlled, double-blind clinical trial","volume":"25","author":"Burkard T","year":"2013","unstructured":"Burkard T, Biedermann A, Herold C, Dietlein M, Rauch M, Diefenbach M. Treatment with a potassium-iron-phosphate-citrate complex improves PSE scores and quality of life in patients with minimal hepatic encephalopathy: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Eur J Gastroenterol Hepatol. 2013, 25:352-8. 10.1097\/MEG.0b013e32835afaa5","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref227","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2021.22.9.2879","article-title":"Efficacy of zinc supplement in minimal hepatic encephalopathy: a prospective, randomized controlled study (Zinc-MHE trial)","volume":"22","author":"Janyajirawong R","year":"2021","unstructured":"Janyajirawong R, Vilaichone RK, Sethasine S. Efficacy of zinc supplement in minimal hepatic encephalopathy: a prospective, randomized controlled study (Zinc-MHE trial). Asian Pac J Cancer Prev. 2021, 22:2879-87. 10.31557\/APJCP.2021.22.9.2879","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref228","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16266","article-title":"Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: a double-blind randomized controlled trial","volume":"38","author":"Sharma BC","year":"2023","unstructured":"Sharma BC, Maharshi S, Sachdeva S, et al.. Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: a double-blind randomized controlled trial. J Gastroenterol Hepatol. 2023, 38:1917-25. 10.1111\/jgh.16266","journal-title":"J Gastroenterol Hepatol"},{"key":"ref229","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840120531","article-title":"Effect of lactulose on the metabolism of short-chain fatty acids","volume":"12","author":"Uribe M","year":"1990","unstructured":"Uribe M, Campollo O, Cot\u00e9 C. Effect of lactulose on the metabolism of short-chain fatty acids. Hepatology. 1990, 12:1251-2. 10.1002\/hep.1840120531","journal-title":"Hepatology"},{"key":"ref230","article-title":"Review: acute versus chronic response to burn injury","volume":"8","author":"Wolfe RR","year":"1981","unstructured":"Wolfe RR. Review: acute versus chronic response to burn injury. Circ Shock. 1981, 8:105-15.","journal-title":"Circ Shock"},{"key":"ref231","doi-asserted-by":"publisher","DOI":"10.1007\/BF01296659","article-title":"Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial","volume":"32","author":"Uribe M","year":"1987","unstructured":"Uribe M, Toledo H, Perez F, et al.. Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial. Dig Dis Sci. 1987, 32:1345-53. 10.1007\/BF01296659","journal-title":"Dig Dis Sci"},{"key":"ref232","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003044.pub3","article-title":"Non-absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"4","author":"Gluud LL","year":"2016","unstructured":"Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016, 4:CD003044. 10.1002\/14651858.CD003044.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref233","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.4746","article-title":"Lactulose vs polyethylene glycol 3350 - electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial","volume":"174","author":"Rahimi RS","year":"2014","unstructured":"Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350 - electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014, 174:1727-33. 10.1001\/jamainternmed.2014.4746","journal-title":"JAMA Intern Med"},{"key":"ref234","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100757","article-title":"Current approaches to hepatic encephalopathy","volume":"27","author":"Vidal-Cevallos P","year":"2022","unstructured":"Vidal-Cevallos P, Ch\u00e1vez-Tapia NC, Uribe M. Current approaches to hepatic encephalopathy. Ann Hepatol. 2022, 27:100757. 10.1016\/j.aohep.2022.100757","journal-title":"Ann Hepatol"},{"key":"ref235","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197101282840414","article-title":"Ammonia production in the human colon","volume":"284","author":"Swales JD","year":"1971","unstructured":"Swales JD, Wrong OM. Ammonia production in the human colon. N Engl J Med. 1971, 284:216-7. 10.1056\/NEJM197101282840414","journal-title":"N Engl J Med"},{"key":"ref236","doi-asserted-by":"publisher","DOI":"10.1185\/03007999709113333","article-title":"Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial","volume":"13","author":"Miglio F","year":"1997","unstructured":"Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin. 1997, 13:593-601. 10.1185\/03007999709113333","journal-title":"Curr Med Res Opin"},{"key":"ref237","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2005.46.3.399","article-title":"Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study","volume":"46","author":"Paik YH","year":"2005","unstructured":"Paik YH, Lee KS, Han KH, et al.. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005, 46:399-407. 10.3349\/ymj.2005.46.3.399","journal-title":"Yonsei Med J"},{"key":"ref238","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.219","article-title":"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","volume":"108","author":"Sharma BC","year":"2013","unstructured":"Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013, 108:1458-63. 10.1038\/ajg.2013.219","journal-title":"Am J Gastroenterol"},{"key":"ref239","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i8.767","article-title":"Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis","volume":"18","author":"Eltawil KM","year":"2012","unstructured":"Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012, 18:767-77. 10.3748\/wjg.v18.i8.767","journal-title":"World J Gastroenterol"},{"key":"ref240","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.16.6087","article-title":"Single d(ApG)\/cis-diamminedichloroplatinum(II) adduct-induced mutagenesis in Escherichia coli","volume":"87","author":"Burnouf D","year":"1990","unstructured":"Burnouf D, Gauthier C, Chottard JC, Fuchs RP. Single d(ApG)\/cis-diamminedichloroplatinum(II) adduct-induced mutagenesis in Escherichia coli. Proc Natl Acad Sci U S A. 1990, 87:6087-91. 10.1073\/pnas.87.16.6087","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref241","article-title":"New approaches to assessing the risks of hyperbilirubinemia","volume":"17","author":"Vohr BR","year":"1990","unstructured":"Vohr BR. New approaches to assessing the risks of hyperbilirubinemia. Clin Perinatol. 1990, 17:293-306.","journal-title":"Clin Perinatol"},{"key":"ref242","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.019","article-title":"Efficacy and safety of ornithine phenylacetate for treating overt hepatic encephalopathy in a randomized trial","volume":"19","author":"Rahimi RS","year":"2021","unstructured":"Rahimi RS, Safadi R, Thabut D, et al.. Efficacy and safety of ornithine phenylacetate for treating overt hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol. 2021, 19:2626-35. 10.1016\/j.cgh.2020.10.019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref243","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318299c789","article-title":"Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study","volume":"47","author":"Ventura-Cots M","year":"2013","unstructured":"Ventura-Cots M, Arranz JA, Sim\u00f3n-Talero M, et al.. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J Clin Gastroenterol. 2013, 47:881-7. 10.1097\/MCG.0b013e318299c789","journal-title":"J Clin Gastroenterol"},{"key":"ref244","article-title":"Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival","volume":"98","author":"Sloane D","year":"2006","unstructured":"Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc. 2006, 98:1934-9.","journal-title":"J Natl Med Assoc"},{"key":"ref245","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012410.pub2","article-title":"L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"5","author":"Goh ET","year":"2018","unstructured":"Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018, 5:CD012410. 10.1002\/14651858.CD012410.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref246","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13666","article-title":"Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy","volume":"32","author":"Sharma BC","year":"2017","unstructured":"Sharma BC, Singh J, Srivastava S, Sangam A, Mantri AK, Trehanpati N, Sarin SK. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2017, 32:1234-9. 10.1111\/jgh.13666","journal-title":"J Gastroenterol Hepatol"},{"key":"ref247","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2019.110693","article-title":"Manipulation of microbiota with probiotics as an alternative for treatment of hepatic encephalopathy","volume":"73","author":"Rivera-Flores R","year":"2020","unstructured":"Rivera-Flores R, Mor\u00e1n-Villota S, Cervantes-Barrag\u00e1n L, L\u00f3pez-Macias C, Uribe M. Manipulation of microbiota with probiotics as an alternative for treatment of hepatic encephalopathy. Nutrition. 2020, 73:110693. 10.1016\/j.nut.2019.110693","journal-title":"Nutrition"},{"key":"ref248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2018.03.006","article-title":"The role of the gut microbiota in the pathology and prevention of liver disease","volume":"60","author":"Altamirano-Barrera A","year":"2018","unstructured":"Altamirano-Barrera A, Uribe M, Ch\u00e1vez-Tapia NC, Nu\u00f1o-L\u00e1mbarri N. The role of the gut microbiota in the pathology and prevention of liver disease. J Nutr Biochem. 2018, 60:1-8. 10.1016\/j.jnutbio.2018.03.006","journal-title":"J Nutr Biochem"},{"key":"ref249","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008716.pub3","article-title":"Probiotics for people with hepatic encephalopathy","volume":"2","author":"Dalal R","year":"2017","unstructured":"Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017, 2:CD008716. 10.1002\/14651858.CD008716.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref250","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2015.05.009","article-title":"Current evidence on the use of probiotics in liver diseases","volume":"17","author":"Ch\u00e1vez-Tapia NC","year":"2015","unstructured":"Ch\u00e1vez-Tapia NC, Gonz\u00e1lez-Rodr\u00edguez L, Jeong M, et al.. Current evidence on the use of probiotics in liver diseases. J Funct Foods. 2015, 17:137-51. 10.1016\/j.jff.2015.05.009","journal-title":"J Funct Foods"},{"key":"ref251","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04574.x","article-title":"Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy","volume":"33","author":"Shukla S","year":"2011","unstructured":"Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther. 2011, 33:662-71. 10.1111\/j.1365-2036.2010.04574.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref252","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(85)80006-8","article-title":"Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus","volume":"88","author":"Uribe M","year":"1985","unstructured":"Uribe M, Dibildox M, Malpica S, et al.. Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus. Gastroenterology. 1985, 88:901-7. 10.1016\/s0016-5085(85)80006-8","journal-title":"Gastroenterology"},{"key":"ref253","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26370","article-title":"The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus","volume":"58","author":"Amodio P","year":"2013","unstructured":"Amodio P, Bemeur C, Butterworth R, et al.. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013, 58:325-36. 10.1002\/hep.26370","journal-title":"Hepatology"},{"key":"ref254","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26314","article-title":"Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy","volume":"57","author":"Laleman W","year":"2013","unstructured":"Laleman W, Simon-Talero M, Maleux G, et al.. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013, 57:2448-57. 10.1002\/hep.26314","journal-title":"Hepatology"},{"key":"ref255","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12771","article-title":"Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy","volume":"39","author":"An J","year":"2014","unstructured":"An J, Kim KW, Han S, Lee J, Lim YS. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014, 39:1418-26. 10.1111\/apt.12771","journal-title":"Aliment Pharmacol Ther"},{"key":"ref256","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj JS","year":"2017","unstructured":"Bajaj JS, Kassam Z, Fagan A, et al.. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017, 66:1727-38. 10.1002\/hep.29306","journal-title":"Hepatology"},{"key":"ref257","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2021.1899277","article-title":"Fecal microbiota transplantation in hepatic encephalopathy: a systematic review","volume":"56","author":"Madsen M","year":"2021","unstructured":"Madsen M, Kimer N, Bendtsen F, Petersen AM. Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. Scand J Gastroenterol. 2021, 56:560-9. 10.1080\/00365521.2021.1899277","journal-title":"Scand J Gastroenterol"},{"key":"ref258","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-12-74","article-title":"A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy","volume":"12","author":"Chavez-Tapia NC","year":"2013","unstructured":"Chavez-Tapia NC, Cesar-Arce A, Barrientos-Guti\u00e9rrez T, Villegas-L\u00f3pez FA, M\u00e9ndez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J. 2013, 12:74. 10.1186\/1475-2891-12-74","journal-title":"Nutr J"},{"key":"ref259","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.05.056","article-title":"Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo","volume":"137","author":"Sharma BC","year":"2009","unstructured":"Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009, 137:885-91. 10.1053\/j.gastro.2009.05.056","journal-title":"Gastroenterology"},{"key":"ref260","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06596.x","article-title":"Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose","volume":"26","author":"Sharma P","year":"2011","unstructured":"Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2011, 26:996-1003. 10.1111\/j.1440-1746.2010.06596.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref261","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"Mullen KD","year":"2014","unstructured":"Mullen KD, Sanyal AJ, Bass NM, et al.. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014, 12:1390-7. 10.1016\/j.cgh.2013.12.021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref262","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni P","year":"2018","unstructured":"Caraceni P, Riggio O, Angeli P, et al.. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018, 391:2417-29. 10.1016\/S0140-6736(18)30840-7","journal-title":"Lancet"},{"key":"ref263","doi-asserted-by":"publisher","DOI":"10.1007\/s002340050686","article-title":"High signal in the adenohypophysis on T1-weighted images presumably due to manganese deposits in patients on long-term parenteral nutrition","volume":"40","author":"Dietemann JL","year":"1998","unstructured":"Dietemann JL, Reimund JM, Diniz RL, et al.. High signal in the adenohypophysis on T1-weighted images presumably due to manganese deposits in patients on long-term parenteral nutrition. Neuroradiology. 1998, 40:793-6. 10.1007\/s002340050686","journal-title":"Neuroradiology"},{"key":"ref264","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.08.069","article-title":"Post-transplant assessment of consciousness in acute-on-chronic liver failure patients undergoing liver transplantation using bispectral index monitoring","volume":"45","author":"Kang SH","year":"2013","unstructured":"Kang SH, Hwang S, Jung BH, et al.. Post-transplant assessment of consciousness in acute-on-chronic liver failure patients undergoing liver transplantation using bispectral index monitoring. Transplant Proc. 2013, 45:3069-71. 10.1016\/j.transproceed.2013.08.069","journal-title":"Transplant Proc"},{"key":"ref265","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2009.01148.x","article-title":"Continuous peritransplant assessment of consciousness using bispectral index monitoring for patients with fulminant hepatic failure undergoing urgent liver transplantation","volume":"24","author":"Hwang S","year":"2010","unstructured":"Hwang S, Lee SG, Park JI, et al.. Continuous peritransplant assessment of consciousness using bispectral index monitoring for patients with fulminant hepatic failure undergoing urgent liver transplantation. Clin Transplant. 2010, 24:91-7. 10.1111\/j.1399-0012.2009.01148.x","journal-title":"Clin Transplant"},{"key":"ref266","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.12.031","article-title":"Factors associated with consciousness recovery time after liver transplantation in recipients with hepatic encephalopathy","volume":"46","author":"Kim KM","year":"2014","unstructured":"Kim KM, Kim GS, Ko JS, Gwak MS, Lee SK, Son MG. Factors associated with consciousness recovery time after liver transplantation in recipients with hepatic encephalopathy. Transplant Proc. 2014, 46:712-5. 10.1016\/j.transproceed.2013.12.031","journal-title":"Transplant Proc"},{"key":"ref267","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.12.038","article-title":"Conscious recovery response in post-hepatic transplant as a function of time-related acute hepatic encephalopathy","volume":"44","author":"Kao TL","year":"2012","unstructured":"Kao TL, Wang CC. Conscious recovery response in post-hepatic transplant as a function of time-related acute hepatic encephalopathy. Transplant Proc. 2012, 44:421-3. 10.1016\/j.transproceed.2011.12.038","journal-title":"Transplant Proc"},{"key":"ref268","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21593","article-title":"Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation","volume":"15","author":"Sotil EU","year":"2009","unstructured":"Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl. 2009, 15:184-92. 10.1002\/lt.21593","journal-title":"Liver Transpl"},{"key":"ref269","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-007-9020-4","article-title":"Perioperative neurological complications after liver transplantation are best predicted by pre-transplant hepatic encephalopathy","volume":"8","author":"Dhar R","year":"2008","unstructured":"Dhar R, Young GB, Marotta P. Perioperative neurological complications after liver transplantation are best predicted by pre-transplant hepatic encephalopathy. Neurocrit Care. 2008, 8:253-8. 10.1007\/s12028-007-9020-4","journal-title":"Neurocrit Care"},{"key":"ref270","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21552","article-title":"Hepatic encephalopathy after liver transplantation in a patient with a normally functioning graft: treatment with embolization of portosystemic collaterals","volume":"15","author":"Herrero JI","year":"2009","unstructured":"Herrero JI, Bilbao JI, Diaz ML, Alegre F, Inarrairaegui M, Pardo F, Quiroga J. Hepatic encephalopathy after liver transplantation in a patient with a normally functioning graft: treatment with embolization of portosystemic collaterals. Liver Transpl. 2009, 15:111-4. 10.1002\/lt.21552","journal-title":"Liver Transpl"},{"key":"ref271","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113249","article-title":"Investigation of post-transplant mental well-being in liver transplant recipients with hepatic encephalopathy","volume":"13","author":"Sarita\u015f S","year":"2024","unstructured":"Sarita\u015f S, Tarlaci S, Bulbuloglu S, Gune\u015f H. Investigation of post-transplant mental well-being in liver transplant recipients with hepatic encephalopathy. J Clin Med. 2024, 13:10.3390\/jcm13113249","journal-title":"J Clin Med"},{"key":"ref272","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2014.11.006","article-title":"Minimal hepatic encephalopathy impairs quality of life","volume":"5","author":"Agrawal S","year":"2015","unstructured":"Agrawal S, Umapathy S, Dhiman RK. Minimal hepatic encephalopathy impairs quality of life. J Clin Exp Hepatol. 2015, 5:S42-8. 10.1016\/j.jceh.2014.11.006","journal-title":"J Clin Exp Hepatol"},{"key":"ref273","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5710.633","article-title":"Method for measuring cerebral dysfunction in patients with liver disease","volume":"2","author":"Zeegen R","year":"1970","unstructured":"Zeegen R, Drinkwater JE, Dawson AM. Method for measuring cerebral dysfunction in patients with liver disease. Br Med J. 1970, 2:633-6. 10.1136\/bmj.2.5710.633","journal-title":"Br Med J"},{"key":"ref274","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL clinical practice guidelines on the management of hepatic encephalopathy","volume":"77","year":"2022","unstructured":"EASL clinical practice guidelines on the management of hepatic encephalopathy. J Hepatol. 2022, 77.807-24. 10.1016\/j.jhep.2022.06.001","journal-title":"J Hepatol"},{"key":"ref275","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02487.x","article-title":"Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis","volume":"16","author":"Das A","year":"2001","unstructured":"Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001, 16:531-5. 10.1046\/j.1440-1746.2001.02487.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref276","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21193","article-title":"Factors associated with poor health-related quality of life of patients with cirrhosis","volume":"120","author":"Marchesini G","year":"2001","unstructured":"Marchesini G, Bianchi G, Amodio P, et al.. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001, 120:170-8. 10.1053\/gast.2001.21193","journal-title":"Gastroenterology"},{"key":"ref277","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03956.x","article-title":"Health-related quality of life in chronic liver disease: the impact of type and severity of disease","volume":"96","author":"Younossi ZM","year":"2001","unstructured":"Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001, 96:2199-205. 10.1111\/j.1572-0241.2001.03956.x","journal-title":"Am J Gastroenterol"},{"key":"ref278","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14824","article-title":"Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients","volume":"48","author":"Labenz C","year":"2018","unstructured":"Labenz C, Baron JS, Toenges G, et al.. Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. Aliment Pharmacol Ther. 2018, 48:313-21. 10.1111\/apt.14824","journal-title":"Aliment Pharmacol Ther"},{"key":"ref279","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-012-9364-0","article-title":"Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients","volume":"28","author":"Nardelli S","year":"2013","unstructured":"Nardelli S, Pentassuglio I, Pasquale C, et al.. Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. Metab Brain Dis. 2013, 28:239-43. 10.1007\/s11011-012-9364-0","journal-title":"Metab Brain Dis"},{"key":"ref280","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-11698","article-title":"Long-term problems after cavopulmonary anastomosis: diagnosis and management","volume":"49","author":"Hess J","year":"2001","unstructured":"Hess J. Long-term problems after cavopulmonary anastomosis: diagnosis and management. Thorac Cardiovasc Surg. 2001, 49:98-100. 10.1055\/s-2001-11698","journal-title":"Thorac Cardiovasc Surg"},{"key":"ref281","doi-asserted-by":"publisher","DOI":"10.1023\/a:1024751420515","article-title":"Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment","volume":"48","author":"Fischbach LA","year":"2003","unstructured":"Fischbach LA, Correa P, Feldman M, Fontham E, Priest E, Goodman KJ, Jain R. Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment. Dig Dis Sci. 2003, 48:1487-94. 10.1023\/a:1024751420515","journal-title":"Dig Dis Sci"},{"key":"ref282","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-013-9393-3","article-title":"Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis","volume":"28","author":"Samanta J","year":"2013","unstructured":"Samanta J, Dhiman RK, Khatri A, Thumburu KK, Grover S, Duseja A, Chawla Y. Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis. Metab Brain Dis. 2013, 28:249-59. 10.1007\/s11011-013-9393-3","journal-title":"Metab Brain Dis"},{"key":"ref283","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00169-2","article-title":"Sleep and liver disease: a bidirectional relationship","volume":"6","author":"Marjot T","year":"2021","unstructured":"Marjot T, Ray DW, Williams FR, Tomlinson JW, Armstrong MJ. Sleep and liver disease: a bidirectional relationship. Lancet Gastroenterol Hepatol. 2021, 6:850-63. 10.1016\/S2468-1253(21)00169-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref284","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237246","article-title":"Minimal hepatic encephalopathy affects daily life of cirrhotic patients: a viewpoint on clinical consequences and therapeutic opportunities","volume":"11","author":"Faccioli J","year":"2022","unstructured":"Faccioli J, Nardelli S, Gioia S, Riggio O, Ridola L. Minimal hepatic encephalopathy affects daily life of cirrhotic patients: a viewpoint on clinical consequences and therapeutic opportunities. J Clin Med. 2022, 11:10.3390\/jcm11237246","journal-title":"J Clin Med"},{"key":"ref285","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283589f49","article-title":"Falls and cognitive dysfunction impair health-related quality of life in patients with cirrhosis","volume":"25","author":"Rom\u00e1n E","year":"2013","unstructured":"Rom\u00e1n E, C\u00f3rdoba J, Torrens M, Guarner C, Soriano G. Falls and cognitive dysfunction impair health-related quality of life in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2013, 25:77-84. 10.1097\/MEG.0b013e3283589f49","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref286","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13345","article-title":"Altered postural control and stability in cirrhotic patients with minimal hepatic encephalopathy correlate with cognitive deficits","volume":"37","author":"Urios A","year":"2017","unstructured":"Urios A, Mangas-Losada A, Gimenez-Garz\u00f3 C, et al.. Altered postural control and stability in cirrhotic patients with minimal hepatic encephalopathy correlate with cognitive deficits. Liver Int. 2017, 37:1013-22. 10.1111\/liv.13345","journal-title":"Liver Int"},{"key":"ref287","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(02)00423-3","article-title":"Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation","volume":"38","author":"Joebges EM","year":"2003","unstructured":"Joebges EM, Heidemann M, Schimke N, Hecker H, Ennen JC, Weissenborn K. Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation. J Hepatol. 2003, 38:273-80. 10.1016\/s0168-8278(02)00423-3","journal-title":"J Hepatol"},{"key":"ref288","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.12.025","article-title":"A model for predicting development of overt hepatic encephalopathy in patients with cirrhosis","volume":"13","author":"Riggio O","year":"2015","unstructured":"Riggio O, Amodio P, Farcomeni A, et al.. A model for predicting development of overt hepatic encephalopathy in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015, 13:1346-52. 10.1016\/j.cgh.2014.12.025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref289","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02265.x","article-title":"The prognostic significance of subclinical hepatic encephalopathy","volume":"95","author":"Hartmann IJ","year":"2000","unstructured":"Hartmann IJ, Groeneweg M, Quero JC, Beijeman SJ, de Man RA, Hop WC, Schalm SW. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol. 2000, 95:2029-34. 10.1111\/j.1572-0241.2000.02265.x","journal-title":"Am J Gastroenterol"},{"key":"ref290","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.11.035","article-title":"Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF)","volume":"51","author":"Montagnese S","year":"2019","unstructured":"Montagnese S, Russo FP, Amodio P, et al.. Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019, 51:190-205. 10.1016\/j.dld.2018.11.035","journal-title":"Dig Liver Dis"},{"key":"ref291","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146076","article-title":"Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy","volume":"11","author":"Thomsen KL","year":"2016","unstructured":"Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PLoS One. 2016, 11:e0146076. 10.1371\/journal.pone.0146076","journal-title":"PLoS One"},{"key":"ref292","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.003","article-title":"Hepatic encephalopathy and fitness to drive","volume":"137","author":"Kircheis G","year":"2009","unstructured":"Kircheis G, Knoche A, Hilger N, Manhart F, Schnitzler A, Schulze H, H\u00e4ussinger D. Hepatic encephalopathy and fitness to drive. Gastroenterology. 2009, 137:1706-15. 10.1053\/j.gastro.2009.08.003","journal-title":"Gastroenterology"},{"key":"ref293","doi-asserted-by":"publisher","DOI":"10.1159\/000507225","article-title":"Role of brain biomarkers S-100-beta and neuron-specific enolase for detection and follow-up of hepatic encephalopathy in cirrhosis before, during and after treatment with L-ornithine-L-aspartate","volume":"27","author":"Strebel H","year":"2020","unstructured":"Strebel H, Haller B, Sohn M, Schepp W, Gundling F. Role of brain biomarkers S-100-beta and neuron-specific enolase for detection and follow-up of hepatic encephalopathy in cirrhosis before, during and after treatment with L-ornithine-L-aspartate. GE Port J Gastroenterol. 2020, 27:391-403. 10.1159\/000507225","journal-title":"GE Port J Gastroenterol"},{"key":"ref294","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000419","article-title":"Association between serum levels of neurofilament light chains and minimal hepatic encephalopathy in patients with liver cirrhosis","volume":"12","author":"Labenz C","year":"2021","unstructured":"Labenz C, Nagel M, K\u00e4mper P, et al.. Association between serum levels of neurofilament light chains and minimal hepatic encephalopathy in patients with liver cirrhosis. Clin Transl Gastroenterol. 2021, 12:e00419. 10.14309\/ctg.0000000000000419","journal-title":"Clin Transl Gastroenterol"},{"key":"ref295","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcaa052.027","article-title":"3-nitro-tyrosine as a biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis","volume":"113","author":"Awad EA","year":"2020","unstructured":"Awad EA, Mohammed MN, Sayyed MM, Elkhayal AE, Ahmed MAS. 3-nitro-tyrosine as a biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. QJM. 2020, 113:hcaa052.027. 10.1093\/qjmed\/hcaa052.027","journal-title":"QJM"},{"key":"ref296","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2021.103242","article-title":"Brain-derived neurotrophic factor as a potential diagnostic marker in minimal hepatic encephalopathy","volume":"7","author":"Stawicka A","year":"2021","unstructured":"Stawicka A, \u015awiderska M, Zbrze\u017aniak J, So\u0142owianowicz N, Woszczenko A, Flisiak R, Jaroszewicz J. Brain-derived neurotrophic factor as a potential diagnostic marker in minimal hepatic encephalopathy. Clin Exp Hepatol. 2021, 7:117-24. 10.5114\/ceh.2021.103242","journal-title":"Clin Exp Hepatol"},{"key":"ref297","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.29179","article-title":"Identifying minimal hepatic encephalopathy: a new perspective from magnetic resonance imaging","volume":"61","author":"Wang Y","year":"2025","unstructured":"Wang Y, Yang L, Shang Y, et al.. Identifying minimal hepatic encephalopathy: a new perspective from magnetic resonance imaging. J Magn Reson Imaging. 2025, 61:11-24. 10.1002\/jmri.29179","journal-title":"J Magn Reson Imaging"},{"key":"ref298","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2022.2111300","article-title":"Altered gut microbiota is associated with sleep disturbances in patients with minimal hepatic encephalopathy caused by hepatitis B-related liver cirrhosis","volume":"16","author":"Luo M","year":"2022","unstructured":"Luo M, Hu FR, Xin RJ, Yao L, Hu SJ, Bai FH. Altered gut microbiota is associated with sleep disturbances in patients with minimal hepatic encephalopathy caused by hepatitis B-related liver cirrhosis. Expert Rev Gastroenterol Hepatol. 2022, 16:797-807. 10.1080\/17474124.2022.2111300","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref299","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1883","article-title":"Evaluation of IL-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis","volume":"6","author":"Gairing SJ","year":"2022","unstructured":"Gairing SJ, Anders J, Kaps L, et al.. Evaluation of IL-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol Commun. 2022, 6:1113-22. 10.1002\/hep4.1883","journal-title":"Hepatol Commun"},{"key":"ref300","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-021-00468-x","article-title":"Identification of minimal hepatic encephalopathy based on dynamic functional connectivity","volume":"15","author":"Cheng Y","year":"2021","unstructured":"Cheng Y, Zhang G, Zhang X, et al.. Identification of minimal hepatic encephalopathy based on dynamic functional connectivity. Brain Imaging Behav. 2021, 15:2637-45. 10.1007\/s11682-021-00468-x","journal-title":"Brain Imaging Behav"},{"key":"ref301","doi-asserted-by":"publisher","DOI":"10.3390\/s23198073","article-title":"Automatic video-oculography system for detection of minimal hepatic encephalopathy using machine learning tools","volume":"23","author":"Calvo C\u00f3rdoba A","year":"2023","unstructured":"Calvo C\u00f3rdoba A, Garc\u00eda Cena CE, Montoliu C. Automatic video-oculography system for detection of minimal hepatic encephalopathy using machine learning tools. Sensors (Basel). 2023, 23:10.3390\/s23198073","journal-title":"Sensors (Basel)"},{"key":"ref302","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011585.pub2","article-title":"Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"7","author":"Zacharias HD","year":"2023","unstructured":"Zacharias HD, Kamel F, Tan J, Kimer N, Gluud LL, Morgan MY. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2023, 7:CD011585. 10.1002\/14651858.CD011585.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref303","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035266","article-title":"Primary prevention of hepatic encephalopathy post-TIPS: a systematic review and meta-analysis","volume":"102","author":"Liang A","year":"2023","unstructured":"Liang A, Brar S, Almaghrabi M, Khan MQ, Qumosani K, Teriaky A. Primary prevention of hepatic encephalopathy post-TIPS: a systematic review and meta-analysis. Medicine (Baltimore). 2023, 102:e35266. 10.1097\/MD.0000000000035266","journal-title":"Medicine (Baltimore)"},{"key":"ref304","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2023.128768","article-title":"Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: a systematic review and meta-analysis","volume":"9","author":"Wibawa ID","year":"2023","unstructured":"Wibawa ID, Mariadi IK, Shalim CP, Sindhughosa DA. Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: a systematic review and meta-analysis. Clin Exp Hepatol. 2023, 9:146-53. 10.5114\/ceh.2023.128768","journal-title":"Clin Exp Hepatol"},{"key":"ref305","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.12896","article-title":"Hepatic encephalopathy and strategies to prevent readmission from inadequate transitions of care","volume":"17","author":"Rosenstengle C","year":"2022","unstructured":"Rosenstengle C, Kripalani S, Rahimi RS. Hepatic encephalopathy and strategies to prevent readmission from inadequate transitions of care. J Hosp Med. 2022, 17:17-23. 10.1002\/jhm.12896","journal-title":"J Hosp Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470578-minimal-hepatic-encephalopathy-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:04:06Z","timestamp":1785913446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470578-minimal-hepatic-encephalopathy-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":305,"URL":"https:\/\/doi.org\/10.7759\/cureus.113978","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}